MCID: ADN012
MIFTS: 43

Adenocarcinoma in Situ

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adenocarcinoma in Situ

MalaCards integrated aliases for Adenocarcinoma in Situ:

Name: Adenocarcinoma in Situ 12 44 15 72

Classifications:



External Ids:

Disease Ontology 12 DOID:4943
MeSH 44 D065311
NCIt 50 C4123
SNOMED-CT 68 51642000
UMLS 72 C0334276

Summaries for Adenocarcinoma in Situ

Disease Ontology : 12 An in situ carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Adenocarcinoma in Situ is related to suppressor of tumorigenicity 3 and appendix adenocarcinoma. An important gene associated with Adenocarcinoma in Situ is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include lung, cervix and testes, and related phenotypes are Reduced mammosphere formation and cellular

Related Diseases for Adenocarcinoma in Situ

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 224, show less)
# Related Disease Score Top Affiliating Genes
1 suppressor of tumorigenicity 3 30.5 CDKN2A CDKN1A
2 appendix adenocarcinoma 30.5 KRT7 KRT20 CDX2
3 endometrial adenocarcinoma 30.4 KRT7 KRAS CDKN2A
4 cervical adenocarcinoma 30.3 KRT7 KRT20 CDX2 CDKN2A CDKN1A
5 bronchiolo-alveolar adenocarcinoma 30.3 KRT7 KRT20 KRAS CDX2
6 endometrial mucinous adenocarcinoma 30.3 PAX2 CDKN2A
7 peritoneum cancer 30.3 PAX8 KRT7
8 duodenum adenocarcinoma 30.2 KRT7 KRAS CDX2
9 dermoid cyst 30.2 KRT7 KRT20
10 villous adenoma 30.0 KRT20 KRAS CDX2
11 glandular cystitis 30.0 KRT7 KRT20 CDX2
12 ovarian mucinous neoplasm 30.0 KRT7 KRT20 CDX2
13 cystic teratoma 30.0 KRT7 KRT20 CDX2
14 transitional cell carcinoma 30.0 KRT7 KRT20 CDKN2A
15 papillary carcinoma 29.9 PAX8 KRT7 KRT20
16 colorectal adenocarcinoma 29.9 KRT7 KRT20 KRAS CDX2
17 mucinous adenocarcinoma 29.8 KRT7 KRT20 KRAS CDX2 CDKN2A
18 mammary paget's disease 29.8 KRT7 KRT20
19 endocervical adenocarcinoma 29.7 PAX8 PAX2 KRT7 KRT20 CDX2 CDKN2A
20 pseudomyxoma peritonei 29.7 KRT7 KRT20 KRAS CDX2
21 intrahepatic cholangiocarcinoma 29.6 KRT7 KRT20 KRAS CDX2
22 colon adenocarcinoma 29.6 KRT20 KRAS CDKN1A
23 papilloma 29.4 KRT7 KRT20 CDKN2A CDKN1A
24 large cell neuroendocrine carcinoma 29.3 KRT7 KRT20
25 barrett esophagus 29.3 MCM2 KRT7 KRT20 CDX2 CDKN2A
26 lung cancer susceptibility 3 28.4 KRT7 KRT20 KRAS H19 CDX2 CDKN2A
27 endometrial cancer 28.4 PAX8 KRT7 KRAS H19 CDKN2A CDKN1A
28 cholangiocarcinoma 28.1 KRT7 KRT20 KRAS H19 CDX2 CDKN2A
29 lung cancer 27.8 KRT7 KRT20 KRAS H19 CDKN2A CDKN1A
30 in situ pulmonary adenocarcinoma 11.4
31 early invasive cervical adenocarcinoma 11.2
32 adenocarcinoma 10.9
33 inverted transitional papilloma 10.6 KRT7 CDKN2A
34 ovary neuroendocrine neoplasm 10.6 KRT7 CDX2
35 anus adenocarcinoma 10.6 KRT7 CDX2
36 mucinous adenofibroma 10.6 KRT7 CDX2
37 bladder carcinoma in situ 10.6 KRT7 CDKN2A
38 adenoid basal cell carcinoma 10.6 KRT7 CDKN2A
39 vulvar disease 10.6 KRT7 CDKN2A
40 cystic basal cell carcinoma 10.6 KRT7 KRT20
41 epithelial predominant wilms' tumor 10.6 KRT7 CDX2
42 anal canal carcinoma 10.6 KRT7 CDKN2A
43 renal pelvis adenocarcinoma 10.6 PAX8 KRT7
44 malignant syringoma 10.6 KRT7 KRT20
45 transverse colon cancer 10.6 KRT7 KRT20
46 alveoli adenoma 10.6 KRT7 KRAS
47 seminal vesicle adenocarcinoma 10.6 KRT7 KRT20
48 endosalpingiosis 10.6 PAX8 KRT7
49 sensory organ benign neoplasm 10.5 PAX8 KRT7
50 well-differentiated liposarcoma 10.5 KRT7 CDKN2A
51 vaginal tubulovillous adenoma 10.5 KRT20 CDX2
52 vaginal adenoma 10.5 KRT20 CDX2
53 krukenberg carcinoma 10.5 KRT7 KRT20
54 vaginal benign neoplasm 10.5 KRT20 CDX2
55 eyelid carcinoma 10.5 KRT7 KRT20
56 papillary transitional carcinoma 10.5 KRT7 KRT20
57 small cell carcinoma of the bladder 10.5 KRT7 KRT20
58 lung acinar adenocarcinoma 10.5 KRT7 KRT20
59 linitis plastica 10.5 KRT7 KRT20
60 large intestine adenocarcinoma 10.5 KRT7 KRT20
61 intratubular embryonal carcinoma 10.5 KRT7 KRT20
62 mucinous ovarian cystadenoma 10.5 KRT7 CDX2
63 adenoid squamous cell carcinoma 10.5 KRT7 KRT20
64 nasal cavity squamous cell carcinoma 10.5 KRT7 CDKN2A
65 bile duct cystadenocarcinoma 10.5 KRT7 KRT20
66 meibomian cyst 10.5 KRT7 KRT20
67 rete testis adenoma 10.5 PAX8 PAX2
68 papillary serous adenocarcinoma 10.5 KRT7 KRT20
69 childhood endodermal sinus tumor 10.5 PAX8 PAX2
70 urethral diverticulum 10.5 PAX8 KRT7
71 bladder lymphoma 10.5 KRT7 KRT20
72 medulloepithelioma 10.5 KRT7 KRT20
73 proliferative verrucous leukoplakia 10.5 MCM2 CDKN2A
74 paget disease, extramammary 10.4 KRT7 KRT20
75 lymphoepithelioma-like carcinoma 10.4 KRT7 KRT20
76 cystadenofibroma 10.4 KRT7 KRT20
77 basaloid squamous cell carcinoma 10.4 KRT7 CDKN2A
78 infiltrative basal cell carcinoma 10.4 KRT7 KRT20
79 cell type benign neoplasm 10.4 KRT7 KRAS CDKN2A
80 anal canal adenocarcinoma 10.4 KRT7 KRAS CDX2
81 eccrine sweat gland neoplasm 10.4 KRT7 KRT20
82 collecting duct carcinoma 10.4 PAX8 KRT7
83 nasal cavity cancer 10.4 KRT7 CDX2 CDKN2A
84 duodenum cancer 10.4 KRT7 KRAS CDX2
85 mucinous cystadenocarcinoma 10.4 KRT7 KRT20
86 thymus lipoma 10.4 KRT7 KRT20
87 necrotizing sialometaplasia 10.4 KRT7 CDKN2A
88 anus cancer 10.4 KRT7 CDX2 CDKN2A
89 endocervical carcinoma 10.4 PAX8 KRT7 CDKN2A
90 cervix uteri carcinoma in situ 10.4
91 cervical intraepithelial neoplasia 10.4
92 ovary epithelial cancer 10.4 PAX8 KRT7 KRAS
93 malignant ovarian surface epithelial-stromal neoplasm 10.4 PAX8 KRT7 KRAS
94 ovarian cancer 1 10.4 PAX8 KRT7 KRAS
95 cervical adenosquamous carcinoma 10.4 PAX8 KRT7 CDKN2A
96 in situ carcinoma 10.3
97 endocrine gland cancer 10.3 PAX8 KRAS CDKN2A
98 bile duct adenoma 10.3 KRT7 KRT20 CDKN2A
99 vulval paget's disease 10.3 KRT7 KRT20 CDKN2A
100 pancreatic mucinous cystadenoma 10.3 KRT7 KRT20
101 glycogen-rich clear cell breast carcinoma 10.3 KRT7 KRT20 CDKN2A
102 pancreatic ductal carcinoma 10.3 KRT7 KRT20 CDKN2A
103 inverted papilloma 10.3 KRT7 KRT20 CDKN2A
104 ovarian cystic teratoma 10.3 KRT7 KRT20
105 small cell carcinoma 10.3 KRT7 KRT20 CDKN2A
106 gastric diffuse adenocarcinoma 10.3 KRT7 KRT20 CDX2
107 cervix endometriosis 10.3 PAX2 MCM2
108 thymus adenocarcinoma 10.3 KRT7 KRT20 CDX2
109 ovarian mucinous adenocarcinoma 10.3 KRT7 KRT20 CDX2
110 jejunal adenocarcinoma 10.3 KRT7 KRT20 CDX2
111 bladder adenocarcinoma 10.3 KRT7 KRT20 CDX2
112 chronic cystitis 10.3 KRT7 KRT20 CDX2
113 rectum adenocarcinoma 10.3 KRT7 KRT20 CDX2
114 ampulla of vater adenocarcinoma 10.3 KRT7 KRT20 CDX2
115 appendix cancer 10.3 KRT7 KRT20 CDX2
116 horseshoe kidney 10.3 KRT7 KRT20 CDX2
117 cystitis cystica 10.3 KRT7 KRT20 CDX2
118 signet ring cell adenocarcinoma 10.3 KRT7 KRT20 CDX2
119 mesothelioma, malignant 10.3 KRT7 KRT20 CDKN2A
120 intestinal obstruction 10.3 KRT7 KRT20 CDX2
121 renal pelvis carcinoma 10.3 PAX8 KRT7 KRT20
122 immune system organ benign neoplasm 10.3 KRT7 KRT20
123 nephrogenic adenoma of urinary bladder 10.3 PAX8 PAX2 KRT7
124 nephrogenic adenoma 10.3 PAX8 PAX2 KRT7
125 bladder benign neoplasm 10.3 PAX8 PAX2 KRT7
126 hidradenocarcinoma 10.3 KRT7 CDX2
127 small cell cancer of the lung 10.3 KRT7 KRT20 CDKN2A
128 kidney benign neoplasm 10.2 PAX8 PAX2 KRT7
129 nephrogenic adenofibroma 10.2 PAX8 PAX2 KRT7
130 bladder urothelial carcinoma 10.2 KRT7 KRT20 KRAS
131 rete testis neoplasm 10.2 PAX8 PAX2 KRT20
132 nasal cavity adenocarcinoma 10.2 KRT7 KRAS CDX2 CDKN2A
133 gastric tubular adenocarcinoma 10.1 KRT7 CDX2
134 cervical cancer 10.1
135 papillary adenocarcinoma 10.1
136 actinic keratosis 10.1 MCM2 KRT20 CDKN2A
137 clear cell renal cell carcinoma 10.1 PAX8 PAX2 KRT7
138 appendix disease 10.1 KRT7 KRT20 KRAS CDX2
139 biliary papillomatosis 10.1 KRT7 KRT20 KRAS CDX2
140 cecum adenocarcinoma 10.1 KRT7 KRT20 KRAS CDX2
141 ampulla of vater cancer 10.1 KRT7 KRT20 KRAS CDX2
142 small intestine cancer 10.1 KRT7 KRT20 KRAS CDX2
143 vulva adenocarcinoma 10.1 KRT7 KRT20 CDX2 CDKN2A
144 endometriosis 10.1
145 mucinous bronchioloalveolar adenocarcinoma 10.1 KRT7 KRT20 CDX2 CDKN2A
146 neuroendocrine carcinoma 10.0
147 adenoma 10.0
148 adenoid cystic carcinoma 10.0 KRT7 KRT20 KRAS
149 squamous cell carcinoma 9.9
150 ovarian brenner tumor 9.9 PAX8 PAX2 KRT7 KRT20
151 clear cell adenocarcinoma 9.9 PAX8 PAX2 KRT7 KRT20
152 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.9
153 cervical polyp 9.9
154 endometrial hyperplasia 9.9
155 hidradenoma 9.9
156 pleomorphic adenoma 9.9
157 adenosquamous carcinoma 9.9
158 gallbladder squamous cell carcinoma 9.9
159 47,xyy 9.9
160 cystic adenomatoid malformation of lung 9.9
161 neuroendocrine carcinoma of the cervix 9.9
162 posttransplant acute limbic encephalitis 9.9
163 gallbladder cancer 9.9 KRAS H19 CDKN2A
164 pilomyxoid astrocytoma 9.8 KRAS H19
165 breast cancer 9.7
166 ovarian cancer 9.7
167 retinoblastoma 9.7
168 thrombophilia due to thrombin defect 9.7
169 thyroid cancer, nonmedullary, 1 9.7
170 androgen insensitivity, partial 9.7
171 leukemia, acute lymphoblastic 3 9.7
172 exanthem 9.7
173 ductal carcinoma in situ 9.7
174 ectopic pregnancy 9.7
175 hydronephrosis 9.7
176 endometriosis of ovary 9.7
177 postmenopausal atrophic vaginitis 9.7
178 squamous cell papilloma 9.7
179 cystitis 9.7
180 neuroendocrine tumor 9.7
181 fallopian tube carcinoma 9.7
182 leiomyosarcoma 9.7
183 vaginitis 9.7
184 hemangioma 9.7
185 cervicitis 9.7
186 cystadenoma 9.7
187 capillary hemangioma 9.7
188 teratoma 9.7
189 fallopian tube adenocarcinoma 9.7
190 cervical squamous cell carcinoma 9.7
191 thyroid gland papillary carcinoma 9.7
192 familial retinoblastoma 9.7
193 papillary hidradenoma 9.7
194 eccrine papillary adenoma 9.7
195 mature teratoma 9.7
196 comedo carcinoma 9.7
197 skin tag 9.7
198 anal gland adenocarcinoma 9.7
199 situs inversus 9.7
200 lupus erythematosus 9.7
201 48,xyyy 9.7
202 complete androgen insensitivity syndrome 9.7
203 polymorphous low-grade adenocarcinoma 9.7
204 urachal adenocarcinoma 9.7
205 urachal cyst 9.7
206 leiomyosarcoma of the cervix uteri 9.7
207 extracranial carotid artery aneurysm 9.7
208 pik3ca-related overgrowth syndrome 9.7
209 thyroid carcinoma 9.7
210 myeloma, multiple 9.7 KRAS H19 CDKN2A
211 breast adenocarcinoma 9.7 KRAS H19 CDKN1A
212 prostatic acinar adenocarcinoma 9.6 PAX8 PAX2 KRT7 KRT20 CDX2
213 wilms tumor 1 9.4 PAX8 PAX2 KRT7 H19
214 adamantinoma of long bones 9.4 KRAS H19 CDKN2A CDKN1A
215 gastrointestinal system cancer 9.4 KRT7 KRAS H19 CDX2 CDKN2A
216 large intestine cancer 9.3 KRT7 KRT20 KRAS CDX2 CDKN2A CDKN1A
217 esophageal cancer 9.1 KRAS H19 CDX2 CDKN2A CDKN1A
218 renal cell carcinoma, nonpapillary 9.1 PAX8 PAX2 KRT7 KRT20 H19
219 pancreatic cancer 9.1 KRAS H19 CDX2 CDKN2A CDKN1A
220 bladder cancer 9.1 KRT20 KRAS H19 CDKN2A CDKN1A
221 gastric adenocarcinoma 9.0 KRT7 KRT20 KRAS H19 CDX2 CDKN2A
222 gastric cancer 8.8 KRT20 KRAS H19 CDX2 CDKN2A CDKN1A
223 hepatocellular carcinoma 8.5 KRT7 KRAS H19 CLDN10 CDKN2A CDKN1A
224 colorectal cancer 8.4 KRT7 KRT20 KRAS H19 CDX2 CDKN2A

Graphical network of the top 20 diseases related to Adenocarcinoma in Situ:



Diseases related to Adenocarcinoma in Situ

Symptoms & Phenotypes for Adenocarcinoma in Situ

GenomeRNAi Phenotypes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

26 (showing 1, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 CLDN1 H19 KRAS KRT7 MCM2 PAX8

MGI Mouse Phenotypes related to Adenocarcinoma in Situ:

46 (showing 6, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.97 CDKN1A CDKN2A CDX2 KRAS KRT7 MCM2
2 embryo MP:0005380 9.87 CDKN1A CDKN2A CDX2 KRAS MCM2 PAX2
3 endocrine/exocrine gland MP:0005379 9.8 CDKN1A CDKN2A CDX2 KRAS MCM2 PAX2
4 neoplasm MP:0002006 9.55 CDKN1A CDKN2A CDX2 KRAS MCM2
5 pigmentation MP:0001186 9.26 CDKN2A KRAS MCM2 PAX2
6 renal/urinary system MP:0005367 9.1 CDKN1A CLDN10 KRAS KRT7 PAX2 PAX8

Drugs & Therapeutics for Adenocarcinoma in Situ

Drugs for Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 31, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4
2 Immunologic Factors Phase 4
3
Sargramostim Approved, Investigational Phase 1, Phase 2 83869-56-1, 123774-72-1
4
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
5
Testosterone Approved, Experimental, Investigational Phase 1, Phase 2 481-30-1, 58-22-0 6013 10204
6
nivolumab Approved Phase 2 946414-94-4
7
Ipilimumab Approved Phase 2 477202-00-9
8
Metformin Approved Phase 2 657-24-9 4091 14219
9 Hormone Antagonists Phase 1, Phase 2
10 Alkylating Agents Phase 1, Phase 2
11 Androgens Phase 1, Phase 2
12 Hormones Phase 1, Phase 2
13 Immunosuppressive Agents Phase 1, Phase 2
14 Antirheumatic Agents Phase 1, Phase 2
15 Antineoplastic Agents, Alkylating Phase 1, Phase 2
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1, Phase 2
17 Antibodies Phase 2
18 Antineoplastic Agents, Immunological Phase 2
19 Immunoglobulins Phase 2
20 Antibodies, Monoclonal Phase 2
21 Hypoglycemic Agents Phase 2
22
acetic acid Approved 64-19-7 176
23
Proflavine Approved 92-62-6 7099
24
Fenbendazole Vet_approved 43210-67-9 3334
25 Hemostatics
26 Coagulants
27 Lugol's solution
28
Retinol acetate 127-47-9 10245972
29 Pharmaceutical Solutions
30 Anti-Infective Agents
31 Anti-Infective Agents, Local

Interventional clinical trials:

(showing 30, show less)
# Name Status NCT ID Phase Drugs
1 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
2 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Recruiting NCT03180034 Phase 4
3 A Prospective Study of Ablation of Pulmonary Focal Pure Ground Glass Opacity Unknown status NCT01429649 Phase 3
4 A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
5 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
6 A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women Completed NCT00834106 Phase 3
7 A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. Completed NCT00128661 Phase 3
8 A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age Recruiting NCT03998254 Phase 3 V503;Gardasil
9 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3
10 Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3
11 A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy Combined With a Granulocytemacrophage-colony Stimulating Factor F-secreting Allogeneic Prostate Cancer Vaccine and Low-dose Cyclophosphamide in Men With High-risk Localized Prostate Cancer Undergoing Radical Prostatectomy Completed NCT01696877 Phase 1, Phase 2 degarelix acetate;Cyclophosphamide;GVAX
12 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
13 Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer: An Internal Pilot Study Active, not recruiting NCT03053544 Phase 2 Metformin
14 Conservative Surgery for Women With Low-risk, Early Stage Cervical Cancer Active, not recruiting NCT01048853 Phase 2
15 Morphometric Diagnosis of Atypical Glandular Lesions Using a Conventional Pap Smear From GOG-0171 Patients (Enrolled by GOG-Japan) With a Cytologic Diagnosis of Atypical Glandular Cells of Unspecified Significance (AGUS) Unknown status NCT00898144
16 Prospective Cohort Study of Telomere Biology Among Patients With Early Adenocarcinoma of the Lung Unknown status NCT02239432
17 Validation of High Resolution Microendoscope in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil) Unknown status NCT03195218
18 Point‐of‐Care, Real‐Time Optical Imaging to Enable Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings Completed NCT02494310
19 Post Colposcopy Management of ASC-US and LSIL Pap Tests (PALS Trial): Pilot Study Completed NCT03466710
20 Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC) Recruiting NCT00892866
21 A Prospective and Multi-center RCT Study of Lymphadenectomy Based on Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma Presenting With Ground Glass Opacity Recruiting NCT03322826
22 Establishment and Evaluation for Pathological Diagnostic Criteria of Intraoperative Frozen Section of Early Stage Lung Cancer Recruiting NCT02941003
23 HSIL/ACIS/Early Cervical Cancer: What Are The Current Causative HPV Subtypes in the Era of HPV Vaccination? Recruiting NCT02937155
24 Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021
25 Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix Active, not recruiting NCT02206048 Proflavine
26 A Clinical Pathway for the Treatment of Multifocal Lung Adenocarcinoma Using Genome Sequencing Active, not recruiting NCT01946100
27 A Prospective, Multi-centre Post Marketing Surveillance (PMS) Cohort Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 L1 VLP AS04 Vaccine in Female Chinese Subjects Aged Between 9 and 45 Years, When Administered According to the Prescribing Information (PI) as Per Routine Practice. Active, not recruiting NCT03438006
28 A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Enrolling by invitation NCT02705404
29 A Long-term Follow-up Registry-based Cohort Study of HPV Vaccine Efficacy Against Cervical Pre-cancerous Lesions and Cervical Cancers in a Cohort of Females Previously Enrolled From Finland in Study HPV-008, as Compared to a Non-intervention Population -Based Reference Cohort of Females From Finland Enrolling by invitation NCT01393470
30 Pilot Study of the Hand-held In Vivo Confocal Microscopy Probe for Detection of Cervical Intraepithelial Neoplasia Suspended NCT02574442

Search NIH Clinical Center for Adenocarcinoma in Situ

Cochrane evidence based reviews: adenocarcinoma in situ

Genetic Tests for Adenocarcinoma in Situ

Anatomical Context for Adenocarcinoma in Situ

MalaCards organs/tissues related to Adenocarcinoma in Situ:

41
Lung, Cervix, Testes, Colon, Lymph Node, Prostate, Pancreas

Publications for Adenocarcinoma in Situ

Articles related to Adenocarcinoma in Situ:

(showing 1226, show less)
# Title Authors PMID Year
1
Increased HPV detection by the use of a pre-heating step on vaginal self-samples analysed by Aptima HPV assay. 38
31002831 2019
2
Endocervical adenocarcinoma in situ (AIS) with ovarian and pulmonary involvement: report of a case and review of the literature suggesting a "seed and soil hypothesis". 38
31309301 2019
3
Should pathologically non-invasive lung adenocarcinoma larger than 3 cm be classified as T1a? 38
31400323 2019
4
Can texture features improve the differentiation of infiltrative lung adenocarcinoma appearing as ground glass nodules in contrast-enhanced CT? 38
31307637 2019
5
Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women. 38
30879979 2019
6
Missed Opportunities for HPV Vaccination Among Vaccine-Eligible Women with High Grade Cervical Lesions. 38
31248688 2019
7
Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis. 38
31319173 2019
8
[Thoracoscopic Left Upper Division Segmentectomy for Multiple Ground-glass Nodules Using Preoperative Virtual-assisted Lung Mapping]. 38
31296803 2019
9
Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. 38
31278276 2019
10
Can we predict histological outcome of distinctive cohorts of patients with glandular cell abnormalities on ThinPrep Papanicolaou testing based on human papillomavirus status, age, and associated squamous abnormalities? 38
31359607 2019
11
Cytological differences between invasive and noninvasive or minimally invasive lung adenocarcinomas diagnosed in Japanese patients using needle biopsy specimens of pulmonary lesions ≤3 cm in diameter. 38
30968597 2019
12
Computer-aided diagnosis of ground-glass opacity pulmonary nodules using radiomic features analysis. 38
31167172 2019
13
Endocervical Adenocarcinoma In Situ Phenotype with Ovarian Metastasis. 38
30599504 2019
14
The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations. 38
31295144 2019
15
Adenocarcinoma in situ of the uterine cervix: Clinical practice guidelines from the Italian society of colposcopy and cervical pathology (SICPCV). 38
31352128 2019
16
Detection of HPV RNA molecules in stratified mucin-producing intraepithelial lesion (SMILE) with concurrent cervical intraepithelial lesion: a case report. 38
31159808 2019
17
Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up. 38
30122646 2019
18
Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination? 38
30536935 2019
19
Adenocarcinoma in situ in type I congenital pulmonary airway malformation. 38
31226882 2019
20
Value of TSCT Features for Differentiating Preinvasive and Minimally Invasive Adenocarcinoma From Invasive Adenocarcinoma Presenting as Subsolid Nodules Smaller Than 3 cm. 38
31201034 2019
21
Application of deep learning (3-dimensional convolutional neural network) for the prediction of pathological invasiveness in lung adenocarcinoma: A preliminary study. 38
31232960 2019
22
Lung Adenocarcinoma Invasiveness Risk in Pure Ground-Glass Opacity Lung Nodules Smaller than 2 cm. 38
29359309 2019
23
Role of ThinPrep liquid-based cytology in evaluation of the endocervical canal in patients with abnormal cervical screening. 38
31186178 2019
24
Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study. 38
31107973 2019
25
Clinicopathological Characteristics of Atypical Glandular Cells Determined by Cervical Cytology in Japan: Survey of Gynecologic Oncology Data from the Obstetrical Gynecological Society of Kinki District, Japan. 38
31048578 2019
26
Clinical analysis of percutaneous computed tomography-guided injection of cyanoacrylate for localization of 115 small pulmonary lesions in 113 asymptomatic patients. 38
30966824 2019
27
Challenges in the Pap diagnosis of endocervical adenocarcinoma in situ. 38
31097290 2019
28
The Incidence and Clinical Significance of Atypical Glandular Cells of Undetermined Significance on Cervical Pap Smears. 38
31242982 2019
29
Expression of Markers of Müllerian Clear Cell Carcinoma in Primary Cervical and Vaginal Gastric-type Adenocarcinomas. 38
29901522 2019
30
CT-guided Microcoil Pulmonary Nodule Localization prior to Video-assisted Thoracoscopic Surgery: Diagnostic Utility and Recurrence-Free Survival. 38
30720402 2019
31
Evaluation of Folate Receptor-Mediated Cervical Dyeing as a Method for Detection of Cervical Lesions. 38
30817686 2019
32
Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women - United States, 2008 and 2016. 38
30998672 2019
33
Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015. 38
30980692 2019
34
Histogram analysis combined with morphological characteristics to discriminate adenocarcinoma in situ or minimally invasive adenocarcinoma from invasive adenocarcinoma appearing as pure ground-glass nodule. 38
30927953 2019
35
A comparison between 2- and 3-dimensional approaches to solid component measurement as radiological criteria for sublobar resection in lung adenocarcinoma ≤ 2 cm in size. 38
30968225 2019
36
RANZCOG Fellows' adherence to guidelines following cytological prediction of cervical adenocarcinoma-in-situ: Cause for concern? 38
30284744 2019
37
Histogram-based models on non-thin section chest CT predict invasiveness of primary lung adenocarcinoma subsolid nodules. 38
30979926 2019
38
Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015. 38
30137283 2019
39
Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. 38
30861114 2019
40
Distinctive clinicopathological features of adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung: A retrospective study. 38
30797486 2019
41
Histopathology of Women with “Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion” (ASC-H) Smears 38
30909664 2019
42
A case study of gastric-type adenocarcinoma in situ of the uterine cervix. 38
30417947 2019
43
Cervical Screening Results Leading to Detection of Adenocarcinoma in Situ of the Uterine Cervix 38
30803195 2019
44
Smear cytological features of large cell neuroendocrine carcinoma of the uterine cervix in pregnancy: A case report and review of the literature. 38
30461217 2019
45
PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes. 38
30282880 2019
46
Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016. 38
30734284 2019
47
An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. 38
30629194 2019
48
Expressions of ATF6, XBP1, and GRP78 in normal tissue, atypical adenomatous hyperplasia, and adenocarcinoma of the lung. 38
30121368 2019
49
Utility of imaging modalities for predicting carcinogenesis in lobular endocervical glandular hyperplasia. 38
31415639 2019
50
Three-dimensional navigation-guided thoracoscopic combined subsegmentectomy for intersegmental pulmonary nodules. 38
30390378 2019
51
New revisions and current issues in the eighth edition of the TNM classification for non-small cell lung cancer. 38
30277521 2019
52
Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer. 38
30291468 2019
53
Radiopathologic correlation of collision lung cancer with ground-glass opacity. 38
30417682 2019
54
Diagnostic ability of percutaneous core biopsy immediately after microwave ablation for lung ground-glass opacity. 38
31436228 2019
55
Trefoil factor family 2 protein: a potential immunohistochemical marker for aiding diagnosis of lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix. 38
30324235 2019
56
Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. 38
30495978 2018
57
Preoperative 3-dimensional computed tomography lung simulation before video-assisted thoracoscopic anatomic segmentectomy for ground glass opacity in lung. 38
30746205 2018
58
Adenocarcinoma of the Lung in Childhood and Adolescence: A Systematic Review. 38
30194036 2018
59
Correlation of tumor spread through air spaces and clinicopathological characteristics in surgically resected lung adenocarcinomas. 38
30527186 2018
60
Systems biology analysis reveals new insights into invasive lung cancer. 38
30547817 2018
61
The predictive value of CT-based radiomics in differentiating indolent from invasive lung adenocarcinoma in patients with pulmonary nodules. 38
29869172 2018
62
Increased risk of recurrence in resected EGFR-positive pN0M0 invasive lung adenocarcinoma. 38
30298562 2018
63
Predictors of Pathologic Tumor Invasion and Prognosis for Ground Glass Opacity Featured Lung Adenocarcinoma. 38
30096292 2018
64
Predictive accuracy of lepidic growth subtypes in early-stage adenocarcinoma of the lung by quantitative CT histogram and FDG-PET. 38
30429012 2018
65
Circulating tumor cell levels and carcinoembryonic antigen: An improved diagnostic method for lung adenocarcinoma. 38
30178907 2018
66
[Changes of lymphatic vessel density in lung adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive adenocarcinoma and the regulatory factors]. 38
30514684 2018
67
Genomic analyses based on pulmonary adenocarcinoma in situ reveal early lung cancer signature. 38
30453959 2018
68
High expression of ovarian cancer immunoreactive antigen domain containing 2 (OCIAD2) is associated with poor prognosis in lung adenocarcinoma. 38
30320419 2018
69
Should minimally invasive lung adenocarcinoma be transferred from stage IA1 to stage 0 in future updates of the TNM staging system? 38
30622797 2018
70
From focal pulmonary pure ground-glass opacity nodule detected by low-dose computed tomography into invasive lung adenocarcinoma: A growth pattern analysis in the elderly. 38
30144287 2018
71
Biliary stricture due to a migrated suture after laparoscopic distal gastrectomy. 38
29464866 2018
72
[Synchronous mucinous metaplasia and neoplasia of the female genital tract]. 38
30423608 2018
73
Atypical carcinoid of the uterine cervix accompanying adenocarcinoma in situ. 38
30154130 2018
74
Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study. 38
30236379 2018
75
Enhanced Detection of Cervical Cancer and Precancer Through Use of Imaged Liquid-Based Cytology in Routine Cytology and HPV Cotesting. 38
30137189 2018
76
New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial. 38
29775805 2018
77
Intraoperatively measured tumor size and frozen section results should be considered jointly to predict the final pathology for lung adenocarcinoma. 38
29752477 2018
78
Adenocarcinoma in situ admixed with small cell neuroendocrine carcinoma of the cervix: A case report with cytological features. 38
29656585 2018
79
The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications. 38
30211037 2018
80
Clinical implications of the innovations in the primary tumour and metastasis of the 8th edition of the TNM classification for lung cancer. 38
30345105 2018
81
Ground glass opacities: Imaging, pathology, and gene mutations. 38
29753514 2018
82
Outcomes of Conservative Management of High Grade Squamous Intraepithelial Lesions in Young Women. 38
29762428 2018
83
Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia. 38
29746299 2018
84
Performance of Conventional Cytology and Colposcopy for the Diagnosis of Cervical Squamous and Glandular Neoplasias. 38
29996168 2018
85
Quantitative CT analysis of pulmonary nodules for lung adenocarcinoma risk classification based on an exponential weighted grey scale angular density distribution feature. 38
29728241 2018
86
Methods for Measuring and Staging a Uterine Cervical Adenocarcinoma Showing Intracystic Papillary Growth: A Case Report. 38
28700431 2018
87
Trends in High-Grade Cervical Cancer Precursors in the Human Papillomavirus Vaccine Era. 38
29778314 2018
88
[Diagnostic value of contrast-enhanced CT scans in identifying lung adenocarcinomas manifesting as ground glass nodules]. 38
30060363 2018
89
Frequency of rare and multi viral high-risk HPV types infection in cervical high grade squamous intraepithelial lesions in a non-native dominant middle eastern country: a polymerase chain reaction-based pilot study. 38
29945637 2018
90
Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions. 38
30050769 2018
91
Anal gland adenocarcinoma in situ with pagetoid spread: a case report. 38
29943205 2018
92
Tumor histology predicts mediastinal nodal status and may be used to guide limited lymphadenectomy in patients with clinical stage I non-small cell lung cancer. 38
29548592 2018
93
Strategy of intentional limited resection for lung adenocarcinoma in situ. 38
30023107 2018
94
[Pigmented extramammary Paget's disease accompanied with condyloma acuminatum: a case report]. 38
29930432 2018
95
[Value of CT Features on Differential Diagnosis of Pulmonary Subsolid Nodules and Degree of invasion Prediction in Pulmonary Adenocarcinoma]. 38
29945703 2018
96
The pattern is the issue: recent advances in adenocarcinoma of the uterine cervix. 38
29404709 2018
97
Utility of Maximum Standard Uptake Value as a Predictor for Differentiating the Invasiveness of T1 Stage Pulmonary Adenocarcinoma. 38
29275041 2018
98
Changes in quantitative CT image features of ground-glass nodules in differentiating invasive pulmonary adenocarcinoma from benign and in situ lesions: histopathological comparisons. 38
29329732 2018
99
CT quantitative parameters to predict the invasiveness of lung pure ground-glass nodules (pGGNs). 38
29397913 2018
100
Cervical small cell carcinoma frequently presented in multiple high risk HPV infection and often associated with other type of epithelial tumors. 38
29788963 2018
101
Radiologic-Pathologic Correlation of Solid Portions on Thin-section CT Images in Lung Adenocarcinoma: A Multicenter Study. 38
29307591 2018
102
Tumor Staging of Lung Cancer: Essential Concepts for the Radiologist. 38
29622074 2018
103
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. 38
29740819 2018
104
Long-term risk of cervical cancer following conization of cervical intraepithelial neoplasia grade 3-A Danish nationwide cohort study. 38
29218720 2018
105
Self-sampling with HPV mRNA analyses from vagina and urine compared with cervical samples. 38
29433016 2018
106
Recent intrauterine device use and the risk of precancerous cervical lesions and cervical cancer. 38
29673740 2018
107
Influence of Ground Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non-Small Cell Lung Cancer. 38
29246833 2018
108
Heterotopic production of ceruloplasmin by lung adenocarcinoma is significantly correlated with prognosis. 38
29572010 2018
109
The prognostic significance of N-myc downregulated gene 1 in lung adenocarcinoma. 38
29431240 2018
110
Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression. 38
29690599 2018
111
What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology? 38
29572008 2018
112
Cervical Adenocarcinoma: A Comparison of the Reproducibility of the World Health Organization 2003 and 2014 Classifications. 38
29474242 2018
113
Nomogram for Predicting the Risk of Invasive Pulmonary Adenocarcinoma for Pure Ground-Glass Nodules. 38
29452996 2018
114
Oncological and reproductive outcomes of adenocarcinoma in situ of the cervix managed with the loop electrosurgical excision procedure. 38
29690868 2018
115
Is a 5-mm diameter an appropriate cut-off value for the diagnosis of atypical adenomatous hyperplasia and adenocarcinoma in situ on chest computed tomography and pathological examination? 38
29780625 2018
116
Establishment of a national cervical screening programme in Ireland, CervicalCheck: the first 6 years. 38
27824660 2018
117
Tissue-based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: A Systematic Review. 38
28582347 2018
118
Tumor-associated CD204+ M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinoma. 38
29274107 2018
119
Adenocarcinoma classification: patterns and prognosis. 38
30259909 2018
120
[Clinical significance of loop electrosurgical excisional procedure in diagnosis and treatment of cervical adenocarcinoma in situ and invasive cervical adenocarcinoma]. 38
29609232 2018
121
[Shanghai Pulmonary Hospital Experts Consensus on the Management of Ground-Glass Nodules Suspected as Lung Adenocarcinoma (Version 1)]. 38
29587930 2018
122
[The Initial Experience of Video-assisted Thoracic Surgery Segmentectomy for Early Stage Lung Cancer]. 38
29526176 2018
123
High proportion of abnormal pap smear tests and cervical dysplasia in women with cystic fibrosis. 38
29245055 2018
124
The developing spectrum of gastric-type cervical glandular lesions. 38
29233547 2018
125
A Clinicopathological Study of Small Lung Adenocarcinoma 1 cm or Less in Size: Emphasis on Histological Subtypes Associated With Lymph Node Metastasis and Recurrence. 38
28805108 2018
126
Uterine cervical adenocarcinoma associated with lobular endocervical glandular hyperplasia: Radiologic-pathologic correlation. 38
29144012 2018
127
HRCT texture analysis for pure or part-solid ground-glass nodules: distinguishability of adenocarcinoma in situ or minimally invasive adenocarcinoma from invasive adenocarcinoma. 38
29273964 2018
128
A novel model uses metabolic and volumetric parameters to predict less invasive lung adenocarcinomas†. 38
28950343 2018
129
Low recurrence rate of high-grade cervical intraepithelial neoplasia after successful excision and routine colposcopy during follow-up. 38
29369205 2018
130
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries. 38
29029053 2018
131
High versus low attenuation thresholds to determine the solid component of ground-glass opacity nodules. 38
30335856 2018
132
Significance of High-Risk Human Papillomavirus Testing for Atypical Glandular Cells on Cervical Cytology. 38
29990964 2018
133
Identification of preoperative prediction factors of tumor subtypes for patients with solitary ground-glass opacity pulmonary nodules. 38
29343293 2018
134
Risk of persistent or recurrent cervical neoplasia in patients with 'pure' adenocarcinoma-in-situ (AIS) or mixed AIS and high-grade cervical squamous neoplasia (cervical intra-epithelial neoplasia grades 2 and 3 (CIN 2/3)): a population-based study. 38
28678394 2018
135
Lung Neoplasms with Low F18-Fluorodeoxyglucose Avidity. 38
29157381 2018
136
A case of urachal villous adenoma with high grade dysplasia focally bordering on adenocarcinoma in situ. 38
29321972 2018
137
Uterine metastases originating from a pulmonary inflammatory myofibroblastic tumor. 38
29578184 2018
138
Coexistence of Cervical Leiomyosarcoma and Gastric-Type Adenocarcinoma In Situ with Extensive Extension to the Endometrium and Fallopian Tube. 38
29670794 2018
139
Myeloid cell leukemia-1 protein expression and myeloid cell leukemia-1 gene amplification in non small cell lung cancer. 38
29567880 2018
140
Prognostic significance of histologic classification and tumor disappearance rate by computed tomography in lung cancer. 38
29600071 2018
141
Human Immunodeficiency Virus (HIV)- and Non-HIV-Associated Immunosuppression and Risk of Cervical Neoplasia. 38
29215531 2018
142
Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma. 38
29387978 2018
143
A Large Retrospective Study of 12714 Cases of LEEP Conization Focusing on Cervical Cancer That Colposcopy-Directed Biopsy Failed to Detect. 38
29854761 2018
144
Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study. 38
29181509 2018
145
Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia. 38
29374658 2018
146
Analysis of pulmonary pure ground-glass nodule in enhanced dual energy CT imaging for predicting invasive adenocarcinoma: comparing with conventional thin-section CT imaging. 38
29312701 2017
147
Computer-Aided Diagnosis of Ground-Glass Opacity Nodules Using Open-Source Software for Quantifying Tumor Heterogeneity. 38
29045176 2017
148
Risk of high-grade lesions after atypical glandular cells in cervical screening: a population-based cohort study. 38
29247086 2017
149
Solitary pulmonary capillary hemangioma presents as ground glass opacity on computed tomography indicating adenocarcinoma in situ/atypical adenomatous hyperplasia: A case report. 38
29188054 2017
150
Occult mucin-producing cholangiocarcinoma in situ: a rare clinical case with difficult tumour staging. 38
28054282 2017
151
Targeted next-generation sequencing for analyzing the genetic alterations in atypical adenomatous hyperplasia and adenocarcinoma in situ. 38
28821955 2017
152
Cervical Adenocarcinoma: Diagnosis of Human Papillomavirus-Positive and Human Papillomavirus-Negative Tumors. 38
28644686 2017
153
Carbon dioxide insufflation and thoracoscopic ultrasonography image of pure ground-glass nodule. 38
28575398 2017
154
Prognostic significance of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage I lung adenocarcinoma: A retrospective study based on analysis of 110 Chinese patients. 38
28834269 2017
155
Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma in situ and minimally invasive adenocarcinoma of lung. 38
29228652 2017
156
Comparison of a radiomic biomarker with volumetric analysis for decoding tumour phenotypes of lung adenocarcinoma with different disease-specific survival. 38
28523350 2017
157
Elevated expression of JAM-A promotes neoplastic properties of lung adenocarcinoma. 38
28837251 2017
158
Cyclophilin A expression and its prognostic significance in lung adenocarcinoma. 38
29027312 2017
159
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. 38
28886907 2017
160
Should the Risk of Invasive Cancer in Pregnancy and the Safety of Loop Electrosurgical Excision Procedure During the First 15 Weeks Change Our Practice? 38
28953123 2017
161
Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009-2012. 38
28765084 2017
162
Positive Correlation Between Clearance of High-Risk Human Papillomavirus and Lack of Residual Disease After Loop Excision of the Transformation Zone in Early Stage Cervical Cancer. 38
28953122 2017
163
Human Papillomavirus-Associated Adenocarcinoma In Situ of the Vestibule. 38
28953132 2017
164
Diagnostic value of contrast-enhanced CT scans in identifying lung adenocarcinomas manifesting as GGNs (ground glass nodules). 38
29068976 2017
165
The prognosis of invasive adenocarcinoma presenting as ground-glass opacity on chest computed tomography after sublobar resection. 38
29268386 2017
166
Case of anal adenocarcinoma in situ with pagetoid spread but without macroscopic abnormality in anal mucosa. 38
27666572 2017
167
Mini-laparoscopic hysterectomy for adenocarcinoma in situ of the uterine cervix using interchangeable 5-mm end effectors: a way to cross the line of minimally invasive surgery in gynaecologic oncology. 38
29479402 2017
168
Two cases of adenocarcinoma in situ arising in lobular endocervical glandular hyperplasia indicating localization of mucin on the cluster surface as an early cytological finding of malignant transformation. 38
28449203 2017
169
Declines in Human Papillomavirus (HPV)-Associated High-Grade Cervical Lesions After Introduction of HPV Vaccines in Connecticut, United States, 2008-2015. 38
28520854 2017
170
Does the histologic predominance of pathological stage IA lung adenocarcinoma influence the extent of resection? 38
28593420 2017
171
Effect of formalin fixation and tumour size in small-sized non-small-cell lung cancer: a prospective, single-centre study. 38
28407385 2017
172
[Advance in Diagnose and Treatment Strategies of Adenocarcinoma in Situ]. 38
28935019 2017
173
Keratin 17 Is a Prognostic Biomarker in Endocervical Glandular Neoplasia. 38
28821199 2017
174
Vaginal and Urine Self-sampling Compared to Cervical Sampling for HPV-testing with the Cobas 4800 HPV Test. 38
28739704 2017
175
Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. 38
28851799 2017
176
HPV-negative Gastric Type Adenocarcinoma In Situ of the Cervix: A Spectrum of Rare Lesions Exhibiting Gastric and Intestinal Differentiation. 38
28394803 2017
177
Cytology versus HPV testing for cervical cancer screening in the general population. 38
28796882 2017
178
HPV vaccines - A review of the first decade. 38
28442134 2017
179
[To analyse the histopathological results of patients with HPV16/18 positive and colposcopic suspicious lesions]. 38
28797154 2017
180
The Association Between Unwanted Sexual Experiences and Early-Onset Cervical Cancer and Precancer by Age 25: A Case-Control Study. 38
27854558 2017
181
Supplement CT-Guided Microcoil Placement for Localising Ground-glass Opacity (GGO) Lesions at "Blind Areas" of the Conventional Hook-Wire Technique. 38
28089791 2017
182
Tissue-based Immunohistochemical Biomarker Accuracy in the Diagnosis of Malignant Glandular Lesions of the Uterine Cervix: A Systematic Review of the Literature and Meta-Analysis. 38
27801764 2017
183
Imaging features of TSCT predict the classification of pulmonary preinvasive lesion, minimally and invasive adenocarcinoma presented as ground glass nodules. 38
28625634 2017
184
Response to: Cutaneous papillary adenocarcinoma in situ. 38
28299799 2017
185
Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma. 38
28347537 2017
186
Ubiquitin-specific protease 8 is a novel prognostic marker in early-stage lung adenocarcinoma. 38
28544031 2017
187
Remedial localization after dislodgement of primary mechanical localization in lung surgery. 38
28616274 2017
188
False-Negative Interpretation of Adenocarcinoma In Situ in the College of American Pathologists Gynecologic PAP Education Program. 38
28301226 2017
189
Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review. 38
28423562 2017
190
Cutaneous papillary adenocarcinoma in situ. 38
28164358 2017
191
Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis. 38
27977543 2017
192
Solitary ground-glass opacity nodules of stage IA pulmonary adenocarcinoma: combination of 18F-FDG PET/CT and high-resolution computed tomography features to predict invasive adenocarcinoma. 38
28423576 2017
193
Risk of persistent or recurrent neoplasia in conservatively treated women with cervical adenocarcinoma in situ with negative histological margins. 38
28181670 2017
194
Risk of persistent and recurrent cervical neoplasia following incidentally detected adenocarcinoma in situ. 38
27908632 2017
195
Value of CT Characteristics in Predicting Invasiveness of Adenocarcinoma Presented as Pulmonary Ground-Glass Nodules. 38
27575275 2017
196
Radiological prediction of tumor invasiveness of lung adenocarcinoma on thin-section CT. 38
28296757 2017
197
Significance of high-risk HPV detection in women with atypical glandular cells on Pap testing: Analysis of 1857 cases from an academic institution. 38
28060456 2017
198
Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. 38
28140453 2017
199
Colonoscopic and histologic features of rectal masses in dogs: 82 cases (1995-2012). 38
28165313 2017
200
A nomogram for predicting the risk of invasive pulmonary adenocarcinoma for patients with solitary peripheral subsolid nodules. 38
27838008 2017
201
Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. 38
28102052 2017
202
Pitfalls and artifacts in the interpretation of oncologic PET/CT of the chest. 38
28298733 2017
203
Conservative Treatment for Patients with Carcinoma in Situ-Positive Margins After a Loop Electroexcisional Procedure: Is It Safe? 38
29999280 2017
204
Predictors of Persistent or Recurrent Disease After Loop Electrosurgical Excision Procedure. 38
27824789 2017
205
Clinical outcomes of patients with metachronous second primary lung adenocarcinomas. 38
28138252 2017
206
Comparison of Cold-Knife Conization versus Loop Electrosurgical Excision for Cervical Adenocarcinoma In Situ (ACIS): A Systematic Review and Meta-Analysis. 38
28125627 2017
207
Paget's Disease of the Vulva Treated with Imiquimod: Case Report and Systematic Review of the Literature. 38
27655036 2017
208
The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases. 38
28704499 2017
209
[The morphological and immunohistochemical characteristics of stratified mucin-producing intraepithelial lesion]. 38
29027524 2017
210
Adenocarcinoma In Situ Arising from Brunner's Gland Treated by Endoscopic Mucosal Resection. 38
28512587 2017
211
SORPTION CORRECTION OF NEPHRON SUB-MICROSCOPIC CHANGES CAUSED BY NEOPLASTIC CHRONIC INTOXICATION WITH THE APPLICATION OF CYTOSTATIC THERAPY. 38
28252422 2017
212
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region. 38
29074187 2016
213
Genome-wide methylome analysis using MethylCap-seq uncovers 4 hypermethylated markers with high sensitivity for both adeno- and squamous-cell cervical carcinoma. 38
27738327 2016
214
The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen. 38
27657992 2016
215
Prognostic considerations of the new World Health Organization classification of lung adenocarcinoma. 38
27903658 2016
216
Diagnosis of lung adenocarcinoma in situ and minimally invasive adenocarcinoma from intraoperative frozen sections: an analysis of 136 cases. 38
27174927 2016
217
Lymph node involvement influenced by lung adenocarcinoma subtypes in tumor size ≤3 cm disease: A study of 2268 cases. 38
27017272 2016
218
Discrepancy of epidermal growth factor receptor mutation in lung adenocarcinoma presenting as multiple ground-glass opacities. 38
27032467 2016
219
Extramammary paget's disease mimicking localized malignancy on cervical cytology. 38
27390216 2016
220
Anatomical Segmentectomy and Wedge Resections Are Associated with Comparable Outcomes for Patients with Small cT1N0 Non-Small Cell Lung Cancer. 38
27496651 2016
221
Lung cancer: a rare indication for, but frequent complication after lung transplantation. 38
27942415 2016
222
[Categorization of uterine cervix tumors : What's new in the 2014 WHO classification]. 38
27770187 2016
223
Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden. 38
27177207 2016
224
Syringocystadenocarcinoma Papilliferum In Situ, a Variant of Cutaneous Adenocarcinoma In Situ: A Case Report With Literature Review. 38
27533073 2016
225
Thin-section computed tomography-histopathologic comparisons of pulmonary focal interstitial fibrosis, atypical adenomatous hyperplasia, adenocarcinoma in situ, and minimally invasive adenocarcinoma with pure ground-glass opacity. 38
27666606 2016
226
Microenvironmental changes in the progression from adenocarcinoma in situ to minimally invasive adenocarcinoma and invasive lepidic predominant adenocarcinoma of the lung. 38
27597281 2016
227
Direct comparison of two vaginal self-sampling devices for the detection of human papillomavirus infections. 38
27434147 2016
228
Epidermal growth factor receptor mutations in adenocarcinoma in situ and minimally invasive adenocarcinoma detected using mutation-specific monoclonal antibodies. 38
27565930 2016
229
Stratified mucin-producing intraepithelial lesion with invasive carcinoma: 12 cases with immunohistochemical and ultrastructural findings. 38
27237368 2016
230
Differential structured illumination microendoscopy for in vivo imaging of molecular contrast agents. 38
27621464 2016
231
Lung Adenocarcinoma: Correlation of Quantitative CT Findings with Pathologic Findings. 38
27097236 2016
232
Cervical polyps: Is histologic evaluation necessary? 38
27465834 2016
233
Gastric-type adenocarcinoma in situ of uterine cervix: cytological and histopathological features of two cases. 38
27334141 2016
234
Extramammary Paget's disease of the oral tissues-literature review and a rare case report. 38
27587306 2016
235
Lung Adenocarcinoma Staging Using the 2011 IASLC/ATS/ERS Classification: A Pooled Analysis of Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma. 38
27137345 2016
236
Synchronous and Metachronous Colon Cancers in Patients with Gastric Cancer: Report of 2 Cases. 38
27990112 2016
237
[Expression of ALK protein in 7 371 pulmonary adenocarcinoma samples, with analysis of clinicopathologic features]. 38
27646887 2016
238
Increased expressions of claudin 4 and 7 in atypical adenomatous hyperplasia and adenocarcinoma of the lung. 38
26872891 2016
239
Three-Dimensional Ground Glass Opacity Ratio in CT Images Can Predict Tumor Invasiveness of Stage IA Lung Cancer. 38
27401643 2016
240
Air bronchogram: A potential indicator of epidermal growth factor receptor mutation in pulmonary subsolid nodules. 38
27393502 2016
241
Pattern-based classification of invasive endocervical adenocarcinoma, depth of invasion measurement and distinction from adenocarcinoma in situ: interobserver variation among gynecologic pathologists. 38
27174588 2016
242
Clinical significance of atypical glandular cells in Pap tests: An analysis of more than 3000 cases at a large academic women's center. 38
27115423 2016
243
Prognostic significance of vascular invasion in intermediate-grade subtype of lung adenocarcinoma. 38
27566971 2016
244
Elucidating Genomic Characteristics of Lung Cancer Progression from In Situ to Invasive Adenocarcinoma. 38
27545006 2016
245
Analysis of the expression and localization of tight junction transmembrane proteins, claudin-1, -4, -7, occludin and JAM-A, in human cervical adenocarcinoma. 38
26847087 2016
246
The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. 38
27107787 2016
247
Findings and Outcomes in a Prevaccination Cohort of Women Younger Than 25 Years Attending a Tertiary Colposcopy Service. 38
27195779 2016
248
Risk of head-and-neck cancer following a diagnosis of severe cervical intraepithelial neoplasia: a nationwide population-based cohort study in Denmark. 38
27106016 2016
249
Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. 38
26755797 2016
250
Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study. 38
26856527 2016
251
Human papillomavirus type-specific persistence and reappearance after successful conization in patients with cervical intraepithelial neoplasia. 38
26614089 2016
252
Surgical pathology of early stage non-small cell lung carcinoma. 38
27429964 2016
253
Evaluating cytology for the detection of invasive cervical cancer. 38
26126636 2016
254
[Strategies of Individual Surgical Treatment for Early Stage Non-small Cell Lung Cancer and the Guidance of Intraoperative Frozen Pathology]. 38
27335298 2016
255
An Unusual Case of Noninvasive Adenocarcinoma Arising in a Localized Adenomyoma of the Gallbladder and Review of Literature. 38
26721302 2016
256
Comparison of outcomes for patients with lepidic pulmonary adenocarcinoma defined by 2 staging systems: A North American experience. 38
26897242 2016
257
The effect of late-phase contrast enhancement on semi-automatic software measurements of CT attenuation and volume of part-solid nodules in lung adenocarcinomas. 38
27161068 2016
258
Clinical performance of the Food and Drug Administration-Approved high-risk HPV test for the detection of high-grade cervicovaginal lesions. 38
26774025 2016
259
Glandular epithelial abnormalities on thinprep® pap tests: Clinical and cytohistologic correlation. 38
26878832 2016
260
Adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive pulmonary adenocarcinoma--analysis of interobserver agreement, survival, radiographic characteristics, and gross pathology in 296 nodules. 38
27067781 2016
261
Oncological Characteristics of Radiological Invasive Adenocarcinoma with Additional Ground-Glass Nodules on Initial Thin-Section Computed Tomography: Comparison with Solitary Invasive Adenocarcinoma. 38
26802286 2016
262
Percutaneous transthoracic localization of pulmonary nodules under C-arm cone-beam CT virtual navigation guidance. 38
27015318 2016
263
Clinical characteristics and advantages of primary peripheral micro-sized lung adenocarcinoma over small-sized lung adenocarcinoma. 38
26374872 2016
264
[Analysis of the reported data of national rural cervical cancer screening project from 2012 to 2013, China]. 38
27029367 2016
265
Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease. 38
26383553 2016
266
Dimethylarginine dimethylaminohydrolase 2 promotes tumor angiogenesis in lung adenocarcinoma. 38
26515557 2016
267
Precise Diagnosis of Intraoperative Frozen Section Is an Effective Method to Guide Resection Strategy for Peripheral Small-Sized Lung Adenocarcinoma. 38
26598742 2016
268
IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis. 38
26744530 2016
269
Assessment of the Utility of PAX8 Immunohistochemical Stain in Diagnosing Endocervical Glandular Lesions. 38
26910219 2016
270
Cervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients. 38
26732782 2016
271
Excisional Treatment of Cervical Dysplasia in Australia 2004-2013: A Population-Based Study. 38
27239196 2016
272
Abnormal uterine cervical cytology in a large tertiary hospital in Bangkok metropolis: Prevalence, management, and outcomes. 38
27146746 2016
273
Stratified Mucin-Producing Intraepithelial Lesion of the Cervix: Subtle Features Not to Be Missed. 38
27442040 2016
274
Pulmonary ground-glass nodules diagnosis: mean change rate of peak CT number as a discriminative factor of pathology during a follow-up. 38
26562098 2016
275
Cytologic findings in stratified mucin-producing intraepithelial lesion of the cervix: A report of 34 cases. 38
26493276 2016
276
High-risk HPV testing in the management of atypical glandular cells: A systematic review and meta-analysis. 38
25583258 2016
277
Low expression levels of putative HPV encoded microRNAs in cervical samples. 38
27818894 2016
278
Radiological and pathological analysis of LDCT screen detected and surgically resected sub-centimetre lung nodules in 44 asymptomatic patients. 38
27579337 2016
279
Practical issues related to uterine pathology: in situ and invasive cervical glandular lesions and their benign mimics: emphasis on cytology-histology correlation and interpretive pitfalls. 38
26715169 2016
280
Endocervical adenocarcinoma: selected diagnostic challenges. 38
26715171 2016
281
Clinical, pathological, and radiological characteristics of solitary ground-glass opacity lung nodules on high-resolution computed tomography. 38
27703366 2016
282
Diagnosis of the invasiveness of lung adenocarcinoma manifesting as ground glass opacities on high-resolution computed tomography. 38
26816547 2016
283
Tumor islands and spread through air spaces: Distinct patterns of invasion in lung adenocarcinoma. 38
26642845 2016
284
Identification of Factors for the Preoperative Prediction of Tumour Subtype and Prognosis in Patients with T1 Lung Adenocarcinoma. 38
28115792 2016
285
Frequencies of ALK rearrangements in lung adenocarcinoma subtypes: a study of 2299 Chinese cases. 38
27386342 2016
286
[New WHO classification of lung adenocarcinoma and preneoplasia]. 38
26791238 2016
287
High-grade Cervical Histopathology in Women with Atypical Glandular Cell Cytology. 38
26838198 2016
288
Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study. 38
27227411 2016
289
Pulmonary Neoplasms in Patients with Birt-Hogg-Dubé Syndrome: Histopathological Features and Genetic and Somatic Events. 38
26974543 2016
290
Quantitative CT analysis of pulmonary ground-glass opacity nodules for distinguishing invasive adenocarcinoma from non-invasive or minimally invasive adenocarcinoma: the added value of using iodine mapping. 38
25981222 2016
291
Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study. 38
26096203 2015
292
Secondhand Tobacco Smoke Exposure and Lung Adenocarcinoma In Situ/Minimally Invasive Adenocarcinoma (AIS/MIA). 38
26503035 2015
293
Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma: A Comparison with the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma. 38
26473646 2015
294
A proteomic profiling of laser-microdissected lung adenocarcinoma cells of early lepidic-types. 38
26162278 2015
295
Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer. 38
26254228 2015
296
The role of video-assisted thoracoscopic surgery in management of the multiple ground-glass nodules. 38
26728679 2015
297
Prognosis and status of lymph node involvement in patients with adenocarcinoma in situ and minimally invasive adenocarcinoma-a systematic literature review and pooled-data analysis. 38
26716039 2015
298
Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons. 38
25417186 2015
299
Glandular Lesions of the Cervix in Clinical Practice: A Cytology, Histology, and Human Papillomavirus Correlation Study From 2 Institutions. 38
25951104 2015
300
Impact of smoking on outcome of resected lung adenocarcinoma. 38
26243355 2015
301
Extrafascial Hysterectomy Without Preoperative Conization is Unacceptable in Patients With Adenocarcinoma in Situ Diagnosed by Cervical Punch Biopsy or Endocervical Curettage. 38
27679125 2015
302
Laparoscopic Oophorectomy and Radical Lymph Node Dissection for a Recurrent Adenocarcinoma In Situ of the Cervix. 38
27678792 2015
303
Cervical Strip Biopsy for High-Grade Cervical Intraepithelial Lesions: a Valid Alternative to Conventional Punch Technique. 38
28435170 2015
304
Comparing Cervical Cytology and Histology Among Human Papillomavirus-Vaccinated and -Unvaccinated Women in an Academic Colposcopy Clinic. 38
26348184 2015
305
Spiradenocarcinoma in Preexisting Spiradenoma With a Large In Situ Adenocarcinoma Component. 38
25830720 2015
306
Perinatal High-Grade Cervical Cytology: A Case Series From a Safety Net Institution. 38
26247258 2015
307
Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma. 38
26496308 2015
308
A novel highly sensitive and specific flow cytometry system for cervical cancer screening. 38
26212521 2015
309
[Early-stage lung cancer manifested as ground-glass opacity]. 38
26654312 2015
310
Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas. 38
26200450 2015
311
Classification of different patterns of pulmonary adenocarcinomas. 38
26313326 2015
312
Correlation between whole tumor size and solid component size on high-resolution computed tomography in the prediction of the degree of pathologic malignancy and the prognostic outcome in primary lung adenocarcinoma. 38
25344503 2015
313
Diagnosis of metachronous multiple lung adenocarcinoma at the cut-end by epidermal growth factor receptor mutation status discordance 4 years after sublobar resection for adenocarcinoma in situ: report of a case. 38
25377270 2015
314
Human Papillomavirus-Related Ovarian Metastasis With Endocervical Adenocarcinoma: Report of 2 Cases and Review of Literature. 38
26360235 2015
315
Incremental value of contrast enhanced computed tomography on diagnostic accuracy in evaluation of small pulmonary ground glass nodules. 38
26543608 2015
316
Negative computer-imaged ThinPrep Pap test and positive hybrid capture2 HPV co-testing results: A quality assurance review. 38
26173579 2015
317
Monitoring Effect of Human Papillomavirus Vaccines in US Population, Emerging Infections Program, 2008-2012. 38
26291379 2015
318
Radiologic Evaluation of Small Lepidic Adenocarcinomas to Guide Decision Making in Surgical Resection. 38
26231858 2015
319
Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. 38
26374070 2015
320
Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States. 38
26098295 2015
321
Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997-2012. 38
26033777 2015
322
Radiologic findings to predict low-grade malignant tumour among clinical T1bN0 lung adenocarcinomas: lessons from histological subtypes. 38
26056324 2015
323
The effect of coexisting squamous cell lesions on prognosis in patients with cervical adenocarcinoma in situ. 38
25956340 2015
324
Stratifin accelerates progression of lung adenocarcinoma at an early stage. 38
26223682 2015
325
Pulmonary adenocarcinoma in situ: analyses of a large series with reference to smoking, driver mutations, and receptor tyrosine kinase pathway activation. 38
25970685 2015
326
The percentage of lepidic growth is an independent prognostic factor in invasive adenocarcinoma of the lung. 38
26159539 2015
327
Conservative Treatment Seems the Best Choice in Adenocarcinoma In Situ of the Cervix Uteri. 38
25943864 2015
328
Radial endobronchial ultrasound images for ground-glass opacity pulmonary lesions. 38
25573408 2015
329
Prognostic significance of promoter CpG island hypermethylation and repetitive DNA hypomethylation in stage I lung adenocarcinoma. 38
25772390 2015
330
Risk of high-grade cervical dysplasia and gynaecological malignancies following the cytologic diagnosis of atypical endocervical cells of undetermined significance: a retrospective study of a state-wide screening population in Western Australia. 38
26044565 2015
331
High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules. 38
25629635 2015
332
Incidence of cervical precancers among HIV-seropositive women. 38
25499260 2015
333
Association of IASLC/ATS/ERS Histologic Subtypes of Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations in 320 Resected Cases. 38
25467929 2015
334
Endocervical adenocarcinoma in situ presenting in fundal endometrial polyp: the mother of all skip lesions. 38
25844546 2015
335
High-resolution computed tomography findings of early mucinous adenocarcinomas and their pathologic characteristics in 22 surgically resected cases. 38
25681135 2015
336
Comparison of cold knife cone biopsy and loop electrosurgical excision procedure in the management of cervical adenocarcinoma in situ: What is the gold standard? 38
25769659 2015
337
Quality evaluation of cone biopsy specimens obtained by large loop excision of the transformation zone. 38
25699117 2015
338
Stratified mucin-producing intraepithelial lesion (SMILE): report of a case series with associated pathological findings. 38
25039487 2015
339
Management of adenocarcinoma in situ of the uterine cervix: a comparison of loop electrosurgical excision procedure and cold knife conization. 38
25089550 2015
340
Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial. 38
25667973 2015
341
Correlations between pathologic subtypes/immunohistochemical implication and CT characteristics of lung adenocarcinoma ≤ 1 cm with ground-glass opacity. 38
25936704 2015
342
What are the radiologic findings predictive of indolent lung adenocarcinoma? 38
25628349 2015
343
Cecal adenocarcinoma presenting as colonic intussusception in adulthood. 38
25829646 2015
344
Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. 38
25681664 2015
345
EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity. 38
25582278 2015
346
Comparison of malignant grade between pure and partially invasive types of early lung adenocarcinoma. 38
25620597 2015
347
Relation between thin-section computed tomography and clinical findings of mucinous adenocarcinoma. 38
25624054 2015
348
[Immunohistochemical evaluation of mutant p53 protein over-expression in non-mucinous adenocarcinoma in-situ and invasive adenocarcinoma, NOS of lung]. 38
26268751 2015
349
HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States. 38
25416715 2015
350
Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study. 38
25596241 2015
351
Age influences the clinical significance of atypical glandular cells on cytology. 38
25667474 2015
352
Which are more correctly diagnosed: conventional Papanicolaou smears or Thinprep samples? A comparative study of 9 years of external quality-assurance testing. 38
25487287 2015
353
Solitary pulmonary metastasis from malignant melanoma of the bulbar conjunctiva presenting as a pulmonary ground glass nodule: Report of a case. 38
26273342 2015
354
Histologic Outcomes in HPV-Positive and Cervical Cytology- Negative Women - Screening Results in Northern Thailand. 38
26514523 2015
355
Clinical Significance of Atypical Squamous Cells of Undetermined Significance among Patients Undergoing Cervical Conization. 38
26745052 2015
356
Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth. 38
25361983 2015
357
Squamous intraepithelial lesions in cervical tissue samples of limited adequacy and insufficient for grading as low or high grade: outcome, clinico-pathological correlates, and predictive role of p16INK4a and Ki67 biomarker staining. 38
24859844 2015
358
Cytological Diagnoses of Adenocarcinoma in situ of the Cervix: Common Misdiagnoses. 38
25766846 2015
359
Coexistence of mature cystic teratoma and adenocarcinoma in situ within atypical proliferative mucinous tumour of ovary--a case report of 35-year-old woman. 38
26050362 2015
360
The utility of human papillomavirus testing in young women with atypical glandular cells on pap test. 38
24769653 2015
361
Cytological variations and typical diagnostic features of endocervical adenocarcinoma in situ: A retrospective study of 74 cases. 38
25972909 2015
362
Adenocarcinoma of the urinary bladder. 38
26309895 2015
363
DNA ploidy and morphology of colon tumors in the adenoma-carcinoma sequence. 38
25677247 2015
364
Expression and prognostic value of GalNAc-T3 in patients with completely resected small (≤2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification. 38
26604783 2015
365
Is Age an Independent Predictor of High-Grade Histopathology in Women Referred for Colposcopy after Abnormal Cervical Cytology? 38
26514516 2015
366
Cervical intraepithelial lesions in females attending Women's Health Clinics in Alexandria, Egypt. 38
26195985 2015
367
Cytology and human papillomavirus co-test results preceding incident high-grade cervical intraepithelial neoplasia. 38
25793987 2015
368
Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucose-uptake in positron emission tomography. 38
25481488 2015
369
Correlation between Serum Carcinoembryonic Antigen Level and Histologic Subtype in Resected Lung Adenocarcinoma. 38
25987049 2015
370
Outcomes of lobectomy in 'active' octogenarians with clinical stage I non-small-cell lung cancer. 38
24747546 2015
371
Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. 38
25987897 2015
372
Multfocal micronodular pneumocyte hyperplasia in a Chinese man masquerading as miliary tuberculosis. 38
25973120 2015
373
Cervical Cancer Screening in an Early Diagnosis and Screening Center in Mersin, Turkey. 38
26514466 2015
374
Human Papillomavirus Genotype Distribution among Thai Women with High-Grade Cervical Intraepithelial Lesions and Invasive Cervical Cancer: a Literature Review. 38
26225645 2015
375
CT findings of persistent pure ground glass opacity: can we predict the invasiveness? 38
25773846 2015
376
Whole-Slide Imaging of Pap Cellblock Preparations Is a Potentially Valid Screening Method. 38
25967603 2015
377
A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. 38
25339396 2015
378
Value of endocervical margin and high-risk human papillomavirus status after conization for high-grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and microinvasive carcinoma of the uterine cervix. 38
25284039 2014
379
Spiradenocarcinoma, cylindrocarcinoma and spiradenocylindrocarcinoma: a clinicopathological study of nine cases. 38
24796384 2014
380
Pathogenesis of combined high-grade squamous intraepithelial lesion and adenocarcinoma in situ of the uterine cervix: human papillomavirus genotype and methylation status and immunohistochemical study. 38
25612672 2014
381
Tailoring surgical treatment of cervical precancerosis. 38
25472455 2014
382
Morphological factors differentiating between early lung adenocarcinomas appearing as pure ground-glass nodules measuring ≤10 mm on thin-section computed tomography. 38
25608623 2014
383
Adenocarcinoma in situ of the uterine cervix--a systematic review. 38
25238167 2014
384
A case of autoimmune pulmonary alveolar proteinosis appearing as a localized ground-glass opacity. 38
25149419 2014
385
Evaluation of the new IASLC/ATS/ERS proposed classification of adenocarcinoma based on lepidic pattern in patients with pathological stage IA pulmonary adenocarcinoma. 38
24890089 2014
386
Cervical intraepithelial neoplasia grade 2 or worse in Galicia, Spain: HPV 16 prevalence and vaccination impact. 38
24274937 2014
387
Partly solid pulmonary nodules: waiting for change or surgery outright? 38
24981106 2014
388
Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. 38
25274978 2014
389
Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts. 38
25349708 2014
390
Monitoring the impact of a national HPV vaccination program in Japan (MINT Study): rationale, design and methods. 38
25098705 2014
391
The IASLC/ATS/ERS classification of lung adenocarcinoma-a surgical point of view. 38
25349706 2014
392
The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects. 38
25349703 2014
393
Predictors of early recurrence for node-negative t1 to t2b non-small cell lung cancer. 38
25134863 2014
394
Reclassification of early stage pulmonary adenocarcinoma and its consequences. 38
25349709 2014
395
Surgical management of pulmonary adenocarcinoma presenting as a pure ground-glass nodule. 38
24566849 2014
396
Managing multifocal bronchioloalveolar carcinoma/lepidic predominant adenocarcinoma: changing rules for an evolving clinical entity. 38
25654480 2014
397
Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients. 38
25064733 2014
398
Unidirectionally thoracoscopic resection of lingual segment of the left upper pulmonary lobe. 38
25276384 2014
399
Cytologic features of stratified mucin producing intraepithelial lesion of the cervix--a case report. 38
24574375 2014
400
The correlation of the International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society (ATS)/European Respiratory Society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. 38
24961844 2014
401
Prediction for prognosis of resected pT1a-1bN0M0 adenocarcinoma based on tumor size and histological status: relationship of TNM and IASLC/ATS/ERS classifications. 38
24976332 2014
402
Unilateral Pigmented Extramammary Paget's Disease of the Axilla Associated with a Benign Mole: A Case Study and a Review of Literature. 38
25214861 2014
403
Identification of mRNAs and lincRNAs associated with lung cancer progression using next-generation RNA sequencing from laser micro-dissected archival FFPE tissue specimens. 38
24735754 2014
404
How best to interpret mixed human papillomavirus genotypes in high-grade cervical intraepithelial neoplasia lesions. 38
24857693 2014
405
Is cervical punch biopsy enough for the management of low-grade cervical intraepithelial neoplasia? 38
24633166 2014
406
Impact of histologic subtyping on outcome in lobar vs sublobar resections for lung cancer: a pilot study. 38
24556743 2014
407
Early lung cancer with lepidic pattern: adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma. 38
24811831 2014
408
Mucosa-associated lymphoid tissue lymphoma presenting as ground glass nodule. 38
26767026 2014
409
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition. 38
24775604 2014
410
Genomic rearrangements define lineage relationships between adjacent lepidic and invasive components in lung adenocarcinoma. 38
24879567 2014
411
[Comparison of blood leptin concentration and colonic mucosa leptin expression in colon adenoma patients and healthy control]. 38
24953612 2014
412
Split-lobe resections versus lobectomy for lung carcinoma of the left upper lobe: a pair-matched case-control study of clinical and oncological outcomes. 38
24179093 2014
413
Colloid carcinoma of the uterine cervix: a case report with respect to immunohistochemical analyses. 38
24681734 2014
414
Recurrent high-grade cervical lesion after primary conization is associated with persistent human papillomavirus infection in Norway. 38
24631451 2014
415
A report of adenocarcinoma in situ and congenital pulmonary airway malformation in a three-day-old infant with a review of the literature. 38
25341604 2014
416
Evaluation of a low-cost liquid-based Pap test in rural El Salvador: a split-sample study. 38
24270191 2014
417
Microinvasive adenocarcinoma of the cervix in a young woman vaccinated against human papillomavirus: the screening must be continued. 38
24270195 2014
418
Papillary adenocarcinoma in situ of the skin: report of four cases. 38
24855569 2014
419
Genomic alterations in pulmonary adenocarcinoma in situ in an adolescent patient. 38
24678688 2014
420
Cervical conization of adenocarcinoma in situ: a predicting model of residual disease. 38
24370689 2014
421
Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. 38
24472852 2014
422
["Crazy paving" of the lungs]. 38
24686759 2014
423
[CT diagnosis of different pathological types of ground-glass nodules]. 38
24785278 2014
424
Cervical Pap screening among Israeli women, 2005-2010. 38
24085583 2014
425
High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil. 38
24405586 2014
426
Jaagsiekte sheep retrovirus detected in human lung cancer tissue arrays. 38
24642139 2014
427
Primary mucinous adenocarcinoma of the renal pelvis with carcinoma in situ in the ureter. 38
24565683 2014
428
Carbonic anhydrase IX is strongly overexpressed in adenocarcinoma in situ of the cervix uteri. 38
24111817 2014
429
Tumour standardized uptake value on positron emission tomography is a novel predictor of adenocarcinoma in situ for c-Stage IA lung cancer patients with a part-solid nodule on thin-section computed tomography scan. 38
24351509 2014
430
[Video-assisted thoracoscopic (VATS) sublobar anatomic resections for lung cancer]. 38
24585198 2014
431
A case of HPV-negative intestinal-type endocervical adenocarcinoma in situ with coexisting multifocal intestinal and gastric metaplasia. 38
24418863 2014
432
Protection against squamous cell carcinoma and cervical adenocarcinoma afforded by cervical cytology screening: a cross-sectional study. 38
24407579 2014
433
Density features of screened lung tumors in low-dose computed tomography. 38
24331263 2014
434
Conventional cytology versus liquid based cytology in cervical pathology: correspondences and inconsistencies in diagnosis, advantages and limits. 38
25611263 2014
435
[Urethral cancer is rare and difficult to diagnose]. 38
25347253 2014
436
The Cellient automated cell block system is useful in the differential diagnosis of atypical glandular cells in Papanicolaou tests. 38
23963870 2014
437
Current readings: radiologic interpretation of the part-solid nodule: clinical relevance and novel technologies. 38
25441005 2014
438
Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. 38
24748806 2014
439
High risk HPV in situ hybridization, p16 INK 4A, and survivin expressions in cervical carcinomas and intraepithelial neoplasms: evaluation of prognostic factors. 38
25556279 2014
440
Residual disease following conization of women with stage IA-IB1 cervical carcinoma in a high incidence region. 38
25227846 2014
441
Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinoma. 38
25152623 2014
442
The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know. 38
25527015 2014
443
Can adenocarcinoma in situ of the uterine cervix be treated safely by conisation in combination with endocervical curettage? 38
25556275 2014
444
Conservative Treatment of Stage IA1 Adenocarcinoma of the Uterine Cervix during Pregnancy: Case Report and Review of the Literature. 38
24716031 2014
445
Tumor size and computed tomography attenuation of pulmonary pure ground-glass nodules are useful for predicting pathological invasiveness. 38
24846292 2014
446
Clinical outcomes of patients with adenocarcinoma in situ of the cervix treated by conization. 38
25556268 2014
447
Quantitative CT analysis of pulmonary ground-glass opacity nodules for the distinction of invasive adenocarcinoma from pre-invasive or minimally invasive adenocarcinoma. 38
25102064 2014
448
Prognostic impact of tumor size eliminating the ground glass opacity component: modified clinical T descriptors of the tumor, node, metastasis classification of lung cancer. 38
24389437 2013
449
Cervical adenocarcinoma identification by testing for chromosomal abnormalities. 38
24283864 2013
450
The prevalence of HPV associated cervical intraepithelial neoplasia in women under age 21: who will be missed under the new cervical cancer screening guidelines? 38
24119656 2013
451
In compressed lung tissue microscopic sections of adenocarcinoma in situ may mimic papillary adenocarcinoma. 38
24283861 2013
452
Laparoscopic ampullectomy for an ampullarian adenoma. 38
23836126 2013
453
Surgical algorithm for heterogeneous bilateral quadruple pulmonary nodules. 38
24057862 2013
454
The value of CT attenuation in distinguishing atypical adenomatous hyperplasia from adenocarcinoma in situ. 38
24229623 2013
455
Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China. 38
24063970 2013
456
Photodynamic therapy for management of cervical intraepithelial neoplasia II and III in young patients and obstetric outcomes. 38
24136239 2013
457
Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study. 38
24043265 2013
458
Pathology and prognosis of persistent stable pure ground-glass opacity nodules after surgical resection. 38
23968760 2013
459
Clinical relevance of the new IASLC/ERS/ATS adenocarcinoma classification. 38
23564952 2013
460
[The new classification of lung adenocarcinoma]. 38
24150851 2013
461
[Correlation analysis between imaging features and lymph node metastasis in T1a lung adenocarcinoma]. 38
24433769 2013
462
Pathologic classification of adenocarcinoma of lung. 38
24006216 2013
463
Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected? 38
25806254 2013
464
Persistent pure ground-glass opacity lung nodules ≥ 10 mm in diameter at CT scan: histopathologic comparisons and prognostic implications. 38
23722583 2013
465
[Case of adenocarcinoma in situ accompanied by an intrapulmonary lymph node with a sarcoid-like reaction]. 38
24511672 2013
466
Long-term follow-up results from women with cervical adenocarcinoma in situ treated by conization: an experience from a large academic women's hospital. 38
23903202 2013
467
HPV-genotypes in high-grade intraepithelial cervical lesions in Danish women. 38
23647074 2013
468
Conization using the Shimodaira-Taniguchi procedure for adenocarcinoma in situ of the uterine cervix. 38
23790263 2013
469
The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland. 38
23463194 2013
470
Surgical treatment of early-stage non-small-cell lung cancer. 38
26217120 2013
471
[Novel morphological and molecular aspects of lung cancer]. 38
23900599 2013
472
Declining rates of high-grade cervical lesions in young women in Connecticut, 2008-2011. 38
23704476 2013
473
[Lung adenocarcinoma in situ which CT showed single pure ground-glass opacity: a case report and literature review]. 38
23945249 2013
474
The new 2011 international association for the study of lung cancer/american thoracic society/european respiratory society classification of lung adenocarcinoma in resected specimens: clinicopathologic relevance and emerging issues. 38
24009626 2013
475
The utility of PAX8 and IMP3 immunohistochemical stains in the differential diagnosis of benign, premalignant, and malignant endocervical glandular lesions. 38
23618832 2013
476
Early-stage pulmonary adenocarcinoma (T1N0M0): a clinical, radiological, surgical, and pathological correlation of 104 cases. The MD Anderson Cancer Center Experience. 38
23542459 2013
477
Only a small fraction of high-grade cervical lesions are discovered after an interpretation of atypical squamous cells of undetermined significance when using imager-assisted, liquid-based papanicolaou tests and the Bethesda 2001 system. 38
22994456 2013
478
Cytology and human papillomavirus screening test results associated with 2827 histopathologic diagnoses of cervical intraepithelial neoplasia 2/3. 38
23050808 2013
479
A cervical abnormality risk prediction model: can we use clinical information to predict which patients with ASCUS/LSIL Pap tests will develop CIN 2/3 or AIS? 38
23486071 2013
480
Results of cytology and high-risk human papillomavirus testing in females with cervical adenocarcinoma in situ. 38
23946807 2013
481
Cervical screening test results associated with 265 histopathologic diagnoses of cervical glandular neoplasia. 38
23765533 2013
482
Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. 38
23468578 2013
483
[The international multidisciplinary classification of lung adenocarcinoma from IASLC/ATS/ERS and problems in clinical practice]. 38
23866662 2013
484
Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study). 38
23777549 2013
485
Naked cuticle Drosophila 1 expression in histologic subtypes of small adenocarcinoma of the lung. 38
23837013 2013
486
Predictive factors of lymph node status in small peripheral non-small cell lung cancers: tumor histology is more reliable. 38
23263905 2013
487
Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix. 38
23541795 2013
488
Cervical intraepithelial neoplasia grade 3 and adenocarcinoma in situ: comparison of ICD-9 codes and pathology results--Kaiser Permanente, United States, 2000-2005. 38
23563889 2013
489
Conization using the Shimodaira-Taniguchi procedure for adenocarcinoma in situ of the uterine cervix. 38
23395556 2013
490
[Adenocarcinoma of the uterine cervix: particularities in diagnosis and treatment]. 38
22921356 2013
491
Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. 38
22913371 2013
492
New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma. 38
23584293 2013
493
Intestinal-type endocervical adenocarcinoma in situ: an immunophenotypically distinct subset of AIS affecting older women. 38
23552379 2013
494
Half century of followup after ureterosigmoidostomy performed in early childhood. 38
23220244 2013
495
Radical treatment of non-small cell lung cancer during the last 5 years. 38
23352436 2013
496
Detection of E2A-PBX1 fusion transcripts in human non-small-cell lung cancer. 38
23688269 2013
497
Bronchioloalveolar invasion in non-small cell lung cancer is associated with expression of transforming growth factor-β1. 38
23705641 2013
498
Subtyping lung adenocarcinoma according to the novel 2011 IASLC/ATS/ERS classification: correlation with patient prognosis. 38
23566969 2013
499
The ground glass opacity component can be eliminated from the T-factor assessment of lung adenocarcinoma. 38
23047267 2013
500
Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. 38
23519309 2013
501
Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma. 38
23591077 2013
502
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. 38
23635684 2013
503
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. 38
23519301 2013
504
Global gene expression differentiating pure bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar carcinoma features. 38
22864788 2013
505
Noninvasive characterization of the histopathologic features of pulmonary nodules of the lung adenocarcinoma spectrum using computer-aided nodule assessment and risk yield (CANARY)--a pilot study. 38
23486265 2013
506
A case of synchronous bilateral lung cancers: EML4-ALK positive adenocarcinoma in the right lung and adenocarcinoma in situ (the former bronchioloalveolar carcinoma) in the left lung. 38
23617234 2013
507
Premalignant lesions of the lower female genital tract: cervix, vagina and vulva. 38
23442737 2013
508
Potential effects of updated pap test screening guidelines and adenocarcinoma in situ of the cervix. 38
23635675 2013
509
Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. 38
23452957 2013
510
Biopsy-site changes in lung adenocarcinoma with prior core needle biopsy: a potential pitfall in the assessment of stromal invasion. 38
23348210 2013
511
New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. 38
23401443 2013
512
APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. 38
23220509 2013
513
Endocervical glandular neoplasia associated with lobular endocervical glandular hyperplasia is HPV-independent and correlates with carbonic anhydrase-IX expression: a Gynaecological Oncology Group Study. 38
23299542 2013
514
An Oncocytic Variant of Intraductal Papillary Neoplasm of the Bile Duct that Formed a Giant Hepatic Cyst. 38
24179642 2013
515
Mucinous cystic neoplasm of the pancreas with neuroendocrine cells and malignant stroma. 38
23299164 2013
516
Clinical characteristics of patients with bronchioloalveolar carcinoma: a retrospective study of 44 cases. 38
23992004 2013
517
Radiologic implications of the 2011 classification of adenocarcinoma of the lung. 38
23070271 2013
518
High pathologic misdiagnosis of cervical adenocarcinoma in situ. 38
24475580 2013
519
Detection of high-risk human papillomavirus subtypes in cervical glandular neoplasia by in situ hybridization. 38
24133595 2013
520
Pulmonary focal fibrosis associated with microscopic arterio-venous fistula manifesting as focal ground-glass opacity on thin-section CT. 38
23316757 2013
521
Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. 38
23242438 2013
522
PAX8 and PAX2 expression in endocervical adenocarcinoma in situ and high-grade squamous dysplasia. 38
23202787 2013
523
Twelve cases of neuroendocrine carcinomas of the uterine cervix: cytology, histopathology and discussion of their histogenesis. 38
23221311 2013
524
Stathmin-1 expression as a complement to p16 helps identify high-grade cervical intraepithelial neoplasia with increased specificity. 38
23211296 2013
525
The mRNA-HPV test utilization in the follow up of HPV related cervical lesions. 38
23016779 2013
526
The immunohistochemical assessment of HPV related adenocarcinoma: pathologic and clinical prognostic significance. 38
23016776 2013
527
Analyses of atypical glandular cells re-defined by the 2006 Bethesda System: histologic outcomes and clinical implication of follow-up management. 38
24475583 2013
528
Current readings: pathology, prognosis, and lung cancer. 38
23800525 2013
529
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia across 5 countries in Asia. 38
23221730 2013
530
Geographic poverty and racial/ethnic disparities in cervical cancer precursor rates in Connecticut, 2008-2009. 38
22515856 2013
531
Treatment patterns for cervical carcinoma in situ in Michigan, 1998-2003. 38
24002133 2013
532
Trends in the incidence of in situ and invasive cervical cancer by age group and histological type in Korea from 1993 to 2009. 38
23977194 2013
533
Radiographic and pathological analysis of small lung adenocarcinoma using the new IASLC classification. 38
23146553 2013
534
Proximity of first sexual intercourse to menarche and risk of high-grade cervical disease. 38
23066159 2012
535
Human papillomavirus genotypes in high-grade cervical lesions in the United States. 38
23045628 2012
536
Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. 38
23137842 2012
537
Diagnostic and therapeutic dilemma associated with atypical glandular cells on liquid-based cervical cytology. 38
22583085 2012
538
Efficacy and safety of human papilloma virus vaccine in cervical cancer prevention: systematic review and meta-analysis. 38
23224305 2012
539
Outcomes of pregnant patients with Pap smears classified as atypical glandular cells. 38
21848610 2012
540
Cytological screening of endocervical adenocarcinoma. 38
23244488 2012
541
Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. 38
23252867 2012
542
Predictive value of negative cone margin status for risk of residual disease among women with cervical adenocarcinoma in situ. 38
22939281 2012
543
CINtec PLUS immunocytochemistry as a tool for the cytologic diagnosis of glandular lesions of the cervix uteri. 38
23086765 2012
544
Utility of conization with frozen section for intraoperative triage prior to definitive hysterectomy. 38
22842126 2012
545
A new classification of adenocarcinoma: what the radiologists need to know. 38
22618632 2012
546
CT-guided percutaneous transthoracic localization of pulmonary nodules prior to video-assisted thoracoscopic surgery using barium suspension. 38
23118567 2012
547
Tubal ligation frequency in Oklahoma women with cervical cancer. 38
22858904 2012
548
IASLC/ATS/ERS International Multidisciplinary Classification of Lung Adenocarcinoma: novel concepts and radiologic implications. 38
23086014 2012
549
Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. 38
23197596 2012
550
Negative predictive value of pap testing: implications for screening intervals for women with human immunodeficiency virus. 38
22996096 2012
551
STAT3 activation and aberrant ligand-dependent sonic hedgehog signaling in human pulmonary adenocarcinoma. 38
22554932 2012
552
Conservative treatment of microinvasive adenocarcinoma of uterine cervix: long-term follow-up. 38
22302130 2012
553
Lesions in patients with multifocal adenocarcinoma are more frequently in the right upper lobes. 38
22733594 2012
554
'Bronchioloalveolar carcinoma': is the term really dead? A critical review of a new classification system for pulmonary adenocarcinomas. 38
22990278 2012
555
Stromal invasion and micropapillary pattern in 212 consecutive surgically resected stage I lung adenocarcinomas: histopathological categories for prognosis prediction. 38
22813729 2012
556
Endocervical glandular involvement, positive endocervical surgical margin and multicentricity are more often associated with high-grade than low-grade squamous intraepithelial lesion. 38
22540878 2012
557
Clinicopathological characteristics of subcentimeter adenocarcinomas of the lung. 38
22727683 2012
558
Incidentally Discovered Adenocarcinoma in situ of the Appendix in a Young Woman. 38
23275764 2012
559
Mixed endocervical adenocarcinoma and high-grade neuroendocrine carcinoma of the cervix with ovarian metastasis of the former component: a report of 2 cases. 38
22833092 2012
560
Cigarette smoking associated with lung adenocarcinoma in situ in a large case-control study (SFBALCS). 38
22814813 2012
561
Histological diagnosis and evaluation of the Swede score colposcopic system in a large cohort of pregnant women with atypical cervical cytology or cervical malignancy signs. 38
22582977 2012
562
A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. 38
22499226 2012
563
Laminin-5 is a biomarker of invasiveness in cervical adenocarcinoma. 38
22898004 2012
564
Conization of the uterine cervix: does the level of gynecologist's training predict margin status? 38
22653354 2012
565
Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. 38
21823117 2012
566
[Markers of stromal invasion during background and precancerous changes of the glandular epithelium and in adenocarcinoma of the cervix uteri]. 38
22997952 2012
567
Desmoplastic stromal response as defined by positive α-smooth muscle actin staining is predictive of invasion in adenocarcinoma of the uterine cervix. 38
22653352 2012
568
Predictors of invasive adenocarcinoma after conization for cervical adenocarcinoma in situ. 38
22410327 2012
569
Papillary carcinoma of thyroid metastatic to adenocarcinoma in situ of lung: report of an unusual case. 38
23110016 2012
570
Transumbilical laparoendoscopic single-site total mesorectal excision for rectal carcinoma. 38
23256013 2012
571
A case of adenocarcinoma in situ of the distal common bile duct diagnosed by percutaneous transhepatic cholangioscopy. 38
22707894 2012
572
Two separate thoroscopic segmentectomies with vessel sealing system. 38
22328623 2012
573
Aberrant stratifin overexpression is regulated by tumor-associated CpG demethylation in lung adenocarcinoma. 38
22310466 2012
574
Fascin expression in endocervical neoplasia: correlation with tumour morphology and growth pattern. 38
22128198 2012
575
Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: an analysis of 166 cases. 38
22188786 2012
576
Frequency of serous tubal intraepithelial carcinoma in various gynecologic malignancies: a study of 300 consecutive cases. 38
22317864 2012
577
Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis. 38
21872356 2012
578
Surgical implications of the new IASLC/ATS/ERS adenocarcinoma classification. 38
21828029 2012
579
[I. Uterine cervical neoplasms 2. Strategy for treatment of adenocarcinoma in situ of uterine cervix and the role of chemotherapy ]. 38
22545284 2012
580
The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. 38
22108842 2012
581
Evaluation of cervical conization as a definitive treatment for microinvasive cervical carcinoma and cervical intraepithelial neoplasia grade 3. 38
21681515 2012
582
The Role of KRAS Mutational Analysis to Determine the Site of Origin of Metastatic Carcinoma to the Lung: A Case Report. 38
23119210 2012
583
Prognostic effect of stromal myofibroblasts in lung adenocarcinoma. 38
22862165 2012
584
Assessment of invasion in lung adenocarcinoma classification, including adenocarcinoma in situ and minimally invasive adenocarcinoma. 38
22214965 2012
585
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. 38
22075171 2012
586
Metastatic adenocarcinoma found in inguinal, pelvic and para-aortic lymph nodes 14 years following hysterectomy for adenocarcinoma in situ of the cervix. 38
24371632 2012
587
Fertility-sparing treatment in younger women with adenocarcinoma in situ of the cervix. 38
22030403 2012
588
Dual stain immunohistochemical localization of p16INK4A and ki-67: a synergistic approach to identify clinically significant cervical mucosal lesions. 38
21602668 2011
589
Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. 38
21491420 2011
590
Using multi-detector-row CT to diagnose ampullary adenoma or adenocarcinoma in situ. 38
21093190 2011
591
[Precancerous lesions of the uterine cervix: morphology and molecular pathology]. 38
21909794 2011
592
[Preneoplastic lesions of pulmonary carcinoma]. 38
22033683 2011
593
[Treatment of adenocarcinoma in situ of the uterine cervix]. 38
22054443 2011
594
HPV genotyping in neuroendocrine carcinoma of the uterine cervix in northern Thailand. 38
21872245 2011
595
High expression of stratifin is a universal abnormality during the course of malignant progression of early-stage lung adenocarcinoma. 38
21207417 2011
596
Do all lung adenocarcinomas follow a stepwise progression? 38
21705107 2011
597
Preoperative differential diagnosis of minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia of the uterine cervix: a multicenter study of clinicopathology and magnetic resonance imaging findings. 38
21685796 2011
598
Incidental gallbladder cancer diagnosed during or after laparoscopic cholecystectomy in members of the Turkish population with gallstone disease. 38
22234759 2011
599
Promoter methylation analysis of WNT/β-catenin signaling pathway regulators to detect adenocarcinoma or its precursor lesion of the cervix. 38
21726894 2011
600
Lobular endocervical glandular hyperplasia with extensive mucinous differentiation of endometrium and endometrial mucinous adenocarcinoma in situ: a case report and review of literature. 38
21605894 2011
601
Risk for residual adenocarcinoma in situ or cervical adenocarcinoma in women undergoing loop electrosurgical excision procedure/conization for adenocarcinoma in situ. 38
22010519 2011
602
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. 38
21926387 2011
603
Mucinous adenocarcinoma of the renal pelvis with adenocarcinoma in situ of the ureter. 38
21976933 2011
604
Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. 38
21642859 2011
605
Histopathology of cervical precursor lesions and cancer. 38
22131112 2011
606
Decreased zinc and downregulation of ZIP3 zinc uptake transporter in the development of pancreatic adenocarcinoma. 38
21613827 2011
607
Follow-up outcomes for a large cohort of US women with negative imaged liquid-based cytology findings and positive high risk human papillomavirus test results. 38
21601911 2011
608
Increased diagnostic accuracy of atypical glandular cells in cervical liquid-based cytology using cell blocks. 38
20726867 2011
609
Pagetoid adenocarcinoma in situ of the cervix with pagetoid spread into the vagina. 38
21768854 2011
610
DNA methylation profile during multistage progression of pulmonary adenocarcinomas. 38
21494759 2011
611
Extramammary Paget's disease of the scrotum. 38
21783099 2011
612
Significance of microscopic invasion into hilar peribronchovascular soft tissue in resection specimens of primary non-small cell lung cancer. 38
21129810 2011
613
Uterine cervical carcinomas associated with lobular endocervical glandular hyperplasia. 38
21771026 2011
614
Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. 38
21684207 2011
615
Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. 38
21684381 2011
616
Clinical significance of atypical glandular cells on Pap smears: experience from a region with a high incidence of cervical cancer. 38
21159042 2011
617
Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. 38
21415357 2011
618
Is the diagnosis of atypical glandular cells of undetermined significance associated with greater risk at an inner city hospital? 38
21682112 2011
619
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. 38
21252858 2011
620
Ground-glass opacity nodules: histopathology, imaging evaluation, and clinical implications. 38
21508733 2011
621
Atypical glandular cells diagnosed during pregnancy and the postpartum period: a retrospective analysis. 38
21227567 2011
622
The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. 38
20506504 2011
623
Follow-up findings in young females with high-grade squamous intraepithelial lesion papanicolaou test results. 38
21366461 2011
624
Cervical adenocarcinoma in situ with negative conization margin: negligible or not? 38
21607088 2011
625
The safety of conization in the management of adenocarcinoma in situ of the uterine cervix. 38
21607092 2011
626
Neoplastic Lesions of the Cervix. 38
26837288 2011
627
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. 38
20949623 2011
628
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. 38
21252716 2011
629
Carbonic anhydrase IX (CA-IX) and high-risk human papillomavirus (H-HPV) as diagnostic biomarkers of cervical dysplasia/neoplasia in Japanese women with a cytologic diagnosis of atypical glandular cells (AGC): a Gynecologic Oncology Group (GOG) Study. 38
21157448 2011
630
"See and treat" approach is appropriate in women with high-grade lesions on either cervical cytology or colposcopy. 38
22126552 2011
631
Endometrial cells in liquid-based cervical cytology: a diagnostic pitfall solved by preparing cytohistology from the residual thin layer sample. 38
21791901 2011
632
KRAS mutation analysis helps to differentiate between pulmonary metastasis from colon adenocarcinoma in situ and primary lung adenocarcinoma. 38
21178719 2011
633
DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. 38
21731750 2011
634
Subcellular localization of the human papillomavirus 16 E7 oncoprotein in CaSki cells and its detection in cervical adenocarcinoma and adenocarcinoma in situ. 38
20970819 2011
635
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. 38
25267916 2011
636
Evaluation of p16INK4a immunohistochemical reactivity in endocervical glandular neoplasia. 38
21192168 2011
637
Cytopathology of adenocarcinoma in situ of the endocervix and its differential diagnosis. 38
21160245 2011
638
Fertility-sparing surgery in early-stage cervical cancer: indications and applications. 38
21147906 2010
639
Cytomorphological criteria, subclassifications of endocervical glandular cell abnormalities, and histopathological outcome: a frequency study. 38
20063408 2010
640
MOLECULAR MARKERS OF EARLY CERVICAL NEOPLASIA. 38
21076641 2010
641
Prospective study of human papillomavirus and risk of cervical adenocarcinoma. 38
20473898 2010
642
Hemorrhagic cholecystitis after anticoagulation therapy. 38
20601855 2010
643
Atypical glandular cells (AGC): ThinPrep Imaging System (TIS), manual screening (MS), and correlation with Hybrid Capture 2 (HC2) HPV DNA testing. 38
20014311 2010
644
ThinPrep Pap test of endocervical adenocarcinoma with lymph node metastasis: report of a case in a 17-year-old woman. 38
19941367 2010
645
Papanicolaou tests associated with cervical mucosal endometriosis: an analysis of cellular features and comparison to endocervical adenocarcinoma in situ. 38
19937768 2010
646
Shimodaira-Taniguchi conization method: its utility and reliability. 38
20683412 2010
647
The two faces of cervical adenocarcinoma in situ. 38
20567153 2010
648
Telomere maintenance and DNA damage responses during lung carcinogenesis. 38
20404006 2010
649
Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus. 38
20518902 2010
650
Morphologic diversity of syringocystadenocarcinoma papilliferum based on a clinicopathologic study of 6 cases and review of the literature. 38
20216201 2010
651
Cytology of cervical intraepithelial glandular lesions. 38
20698109 2010
652
Digital colposcopy for the diagnosis of cervical adenocarcinoma using a narrow band imaging system. 38
20686380 2010
653
HPV genotyping and HPV16 variant analysis in glandular and squamous neoplastic lesions of the uterine cervix. 38
20207397 2010
654
The Pittsburgh Cervical Cancer Screening Model: a risk assessment tool. 38
20441506 2010
655
Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. 38
20414103 2010
656
Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. 38
20423964 2010
657
BD focalpoint slide profiler performance with atypical glandular cells on SurePath Papanicolaou smears. 38
20209621 2010
658
An immunohistochemical study of cervical neuroendocrine carcinomas: Neoplasms that are commonly TTF1 positive and which may express CK20 and P63. 38
20182342 2010
659
Diagnostic value and implications of vimentin expression in normal, reactive and neoplastic endocervical epithelium. 38
20350213 2010
660
Cyclin D1 immunoreactivity in normal endocervix and diagnostic value in reactive and neoplastic endocervical lesions. 38
20062011 2010
661
Bronchioloalveolar Carcinoma and Minimally Invasive Adenocarcinoma. 38
26839025 2010
662
Stepwise progression of pulmonary adenocarcinoma--clinical and molecular implications. 38
20108111 2010
663
Simultaneous squamous cell carcinoma in situ and adenocarcinoma in situ of the uterine cervix in a 36-year-old Japanese woman. 38
19693522 2010
664
The management of women with abnormal cervical cytology in pregnancy. 38
19805007 2010
665
PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. 38
20061933 2010
666
Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens. 38
19952938 2010
667
[Our and foreign experience in surgical treatment of CIN III-cold knife conisation versus LLETZ]. 38
20734649 2010
668
Endocervical adenocarcinoma in situ with ovarian metastases: a unique variant with potential for long-term survival. 38
19952931 2010
669
Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. 38
20073612 2010
670
Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. 38
21147870 2010
671
Diverse glandular pathologies coexist with high-grade squamous intraepithelial lesion in cyto-histological review of atypical glandular cells on ThinPrep specimens. 38
18522633 2009
672
Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study. 38
19788587 2009
673
Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. 38
19670419 2009
674
Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years. 38
20129072 2009
675
Histologic correlates of glandular abnormalities in cervical cytology among women with human immunodeficiency virus. 38
20168108 2009
676
The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. 38
19453788 2009
677
Single-port access laparoscopic radical left colectomy in humans. 38
19966617 2009
678
[Clinical significance on atypical cervical glandular cytology]. 38
20137603 2009
679
Performance of the cytologic examination for the diagnosis of endocervical adenocarcinoma in situ: cytologic-histologic correlation in 60 cases. 38
19798884 2009
680
Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. 38
19535524 2009
681
Impact of a quadrivalent HPV6/11/16/18 vaccine in Mexican women: public health implications for the region. 38
19853193 2009
682
Endoscopic management of large colorectal polyps. 38
19259689 2009
683
An audit of standards of the 'see and treat' approach in women with a high-grade squamous intraepithelial lesion on Pap smears. 38
19603324 2009
684
Update on ASCCP consensus guidelines for abnormal cervical screening tests and cervical histology. 38
19621855 2009
685
Endoclipping for gastric perforation secondary to second session of EMRC in locally residual early gastric cancer: a case report. 38
18620913 2009
686
Fortuitous detection of endocervical adenocarcinoma in situ: a report of 2 cases. 38
19691263 2009
687
History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. 38
19651367 2009
688
The role of loop electrosurgical excisional procedure in the management of adenocarcinoma in situ of the uterine cervix. 38
19428171 2009
689
Accuracy of Thinprep Imaging System in detecting atypical glandular cells. 38
19185007 2009
690
Misleading initial histological diagnosis of a polymorphous low-grade adenocarcinoma in situ ex pleomorphic adenoma-a case report. 38
19189140 2009
691
Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. 38
19295407 2009
692
Current concepts in cervical pathology. 38
19415947 2009
693
Human papillomavirus-specific genotypes in cervical lesions of women referred for smears with atypical glandular cells or adenocarcinoma in situ. 38
19620946 2009
694
Cervical adenocarcinoma in situ recurring as vaginal adenocarcinoma 16 years after hysterectomy. 38
19620950 2009
695
Use of human papillomavirus testing in the management of atypical glandular cells. 38
19387129 2009
696
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. 38
19236277 2009
697
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. 38
19236279 2009
698
Intramucosal adenocarcinoma of the ileum originated 40 years after ileosigmoidostomy. 38
19379525 2009
699
Clinical significance of atypical glandular cells in conventional pap smears in a large, high-risk U.S. west coast minority population. 38
19365967 2009
700
Endocervical adenocarcinoma in situ, serous type. 38
19188821 2009
701
A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. 38
19188825 2009
702
Upregulation of MUC4 in cervical squamous cell carcinoma: pathologic significance. 38
19188823 2009
703
High-risk HPV types in lesions of the uterine cervix of female commercial sex workers in the Philippines. 38
19152419 2009
704
Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status. 38
19019325 2009
705
Enhanced L1CAM expression on pancreatic tumor endothelium mediates selective tumor cell transmigration. 38
18931829 2009
706
Reappraisal of synchronous and multifocal mucinous lesions of the female genital tract: a close association with gastric metaplasia. 38
19207943 2009
707
Pulmonary adenocarcinomas: classification and reporting. 38
19187177 2009
708
[Experimental vaccines for sexually transmitted infections]. 38
19514600 2009
709
Presence of endometrial adenocarcinoma in situ in complex atypical endometrial hyperplasia is associated with increased incidence of endometrial carcinoma in subsequent hysterectomy. 38
19116629 2009
710
[Clinico-morphological diagnosis of adenocarcinoma in situ of the cervix uteri]. 38
20210017 2009
711
Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. 38
18813124 2008
712
Management of atypical glandular cells and adenocarcinoma in situ. 38
19061821 2008
713
Synchronous high-grade squamous intraepithelial lesion and adenocarcinoma in situ of cervix in a young woman presenting with hyperchromatic crowded groups in the cervical cytology specimen: report of a case. 38
18831021 2008
714
Detection of HPV-induced cervical (pre) neoplastic lesions: a tissue microarray (TMA) study. 38
18542030 2008
715
Clinical impact of preoperative screening for gastric mucin secretion in cervical discharge by HIK1083-labeled latex agglutination test. 38
18794052 2008
716
Clinical relevance of atypical squamous cells of undetermined significance by the 2001 bethesda system: experience from a cervical cancer high incidence region. 38
19256777 2008
717
Erosive vulvar lichen planus: a cohort at risk for cancer? 38
19004404 2008
718
The colposcopic examination. 38
18761298 2008
719
Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. 38
18670358 2008
720
Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: pathologic pitfalls and the application of an objective scoring system. 38
18635252 2008
721
Clonality and HPV infection analysis of concurrent glandular and squamous lesions and adenosquamous carcinomas of the uterine cervix. 38
18701412 2008
722
Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology. 38
18548530 2008
723
Human papillomavirus vaccines versus cervical cancer screening. 38
18538554 2008
724
Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. 38
18580321 2008
725
Adenocarcinoma in situ arising in vulvar papillary hidradenoma: report of 2 cases. 38
18580327 2008
726
Atypical glandular cells and adenocarcinoma in situ according to the Bethesda 2001 classification: cytohistological correlation and clinical implications. 38
17933453 2008
727
[Persistence and recurrence of in situ cervical adenocarcinoma after primary treatment. About 121 cases]. 38
18539502 2008
728
[Local excision of giant rectal polypoid neoplasms]. 38
18709772 2008
729
Cytologic features of endocervical glandular lesions: comparison of SurePath, ThinPrep, and conventional smear specimen preparations. 38
18335553 2008
730
Low p53 and retinoblastoma protein expression in cervical intraepithelial neoplasia grade 3 lesions is associated with coexistent adenocarcinoma in situ. 38
18234283 2008
731
Endocervical glandular cell abnormalities in conventional cervical smears: evaluation of the performance of cytomorphological criteria and HPV testing in predicting neoplasia. 38
18205627 2008
732
Intraepidermal adenocarcinoma in the perianal skin of two cats, a condition resembling human extramammary Paget's disease. 38
18177290 2008
733
Endometrial hyperplasia and carcinoma in endometrial polyps: clinicopathologic and follow-up findings. 38
18156974 2008
734
Role of medial pancreatectomy in the management of intraductal papillary mucinous neoplasms and islet cell tumors of the pancreatic neck and body. 38
18292661 2008
735
Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. 38
18156982 2008
736
A breast cancer patient with pelvic and gastric malignancy after adjuvant tamoxifen treatment for breast cancer. 38
18459568 2008
737
Significant decrease of adenocarcinoma in situ not reflected in cervical adenocarcinoma incidence in the Netherlands 1989-2003. 38
18182979 2008
738
Cold knife versus laser cone biopsy for adenocarcinoma in situ of the cervix--a comparison of management and outcome. 38
17506846 2008
739
Comparative sensitivities of ThinPrep and Papanicolaou smear for adenocarcinoma in situ (AIS) and combined AIS/high-grade squamous intraepithelial lesion (HSIL): comparison with HSIL. 38
17969065 2007
740
A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment. 38
18086769 2007
741
Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. 38
18162241 2007
742
[Quadrivalent HPV 6/11/16/18 vaccine]. 38
18078651 2007
743
Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix. 38
17689593 2007
744
Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. 38
18008221 2007
745
Overexpression of CYP2A6 in human colorectal tumors. 38
17683511 2007
746
2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. 38
17917567 2007
747
2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. 38
17904956 2007
748
Morphological changes in endometrium of hemodialyzed women of reproductive age. 38
17943547 2007
749
Differential expression of cyclin-dependent kinase inhibitors and apoptosis-related proteins in endocervical lesions. 38
17693084 2007
750
Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. 38
17618248 2007
751
Intestinal type adenocarcinoma in situ of the cervix. 38
17703459 2007
752
Cervical adenocarcinoma in situ: the predictive value of conization margin status. 38
17689647 2007
753
Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ (AIS) of the uterine cervix. 38
17481701 2007
754
Subacute lupus erythematosus-like rash associated with oesophageal adenocarcinoma in situ. 38
17376201 2007
755
Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. 38
17580276 2007
756
Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. 38
17544766 2007
757
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. 38
17494925 2007
758
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. 38
17494926 2007
759
How can the overtreatment rate of "see and treat" approach be reduced in women with high-grade squamous intraepithelial lesion on cervical cytology? 38
17696732 2007
760
Factors affecting residual lesion in women with cervical adenocarcinoma in situ after cone excisional biopsy. 38
17696736 2007
761
Distribution of human papillomavirus types in different histological subtypes of cervical adenocarcinoma. 38
17600937 2007
762
Predictive factors of malignant or invasive intraductal papillary-mucinous neoplasms of the pancreas. 38
17458608 2007
763
S100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct. 38
17276942 2007
764
A distinctive set of genes is upregulated during the inflammation-carcinoma sequence in mouse stomach infected by Helicobacter felis. 38
17101721 2007
765
IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. 38
17192788 2007
766
HPV vaccine and its recommendations, 2007. 38
17270106 2007
767
Immunohistochemistry as a diagnostic aid in cervical pathology. 38
17365826 2007
768
Redefining early cervical neoplasia: recent progress. 38
17198305 2007
769
Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions. 38
17197900 2007
770
Sensitivity and specificity of the Pap smear for glandular lesions of the cervix and endometrium. 38
17328495 2007
771
Prophylactic laparoscopic-assisted total gastrectomy for hereditary diffuse gastric cancer. 38
17651578 2007
772
HPV DNA testing as an adjunct in the management of patients with low grade cytological lesions in Finland. 38
17364315 2007
773
Endocervical glandular lesions: a diagnostic approach combining a semi-quantitative scoring method to the expression of CEA, MIB-1 and p16. 38
16876235 2006
774
Interlaboratory reproducibility of atypical glandular cells of undetermined significance: a national survey. 38
17168918 2006
775
[Glandular premalignant lesions of the uterine cervix]. 38
17236402 2006
776
Clinicopathologic features of early adenocarcinoma of the cervix initially managed with cervical conization. 38
16860853 2006
777
Laser cylindrical excision for cervical adenocarcinoma in situ. 38
16999959 2006
778
[Management of in situ cervical adenocarcinoma]. 38
17097907 2006
779
Atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): a result not to be ignored. 38
17169233 2006
780
Pathological characteristics of cervical adenocarcinoma in a multi-center US-based study. 38
16697450 2006
781
Preserving fertility in invasive cervical adenocarcinoma by abdominal radical trachelectomy and pelvic lymphadenectomy. 38
17061618 2006
782
Can adenocarcinoma in situ of the uterine cervix be predicted before cervical conization? 38
17250421 2006
783
Mucinous expression in benign and neoplastic glandular lesions of the uterine cervix. 38
17090193 2006
784
Variants of human papillomavirus types 16 and 18: histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in cervical smear. 38
16990718 2006
785
Biliary cystic tumors with bile duct communication: a cystic variant of intraductal papillary neoplasm of the bile duct. 38
16741522 2006
786
Adenocarcinoma in situ arising in a tubulopapillary apocrine hidradenoma of the peri-anal region. 38
17101482 2006
787
Villoglandular adenocarcinoma in situ of intestinal type of the hymen: de novo origin from squamous mucosa? 38
16829755 2006
788
Northern Thai women with high grade squamous intraepithelial lesion on cervical cytology have high prevalence of underlying invasive carcinoma. 38
17059349 2006
789
Rate of pathology from atypical glandular cell Pap tests classified by the Bethesda 2001 nomenclature. 38
16738153 2006
790
Prediction of high-grade cervical disease with human papillomavirus detection in women with glandular and squamous cytologic abnormalities. 38
16803485 2006
791
Validation of tissue microarray technology using cervical adenocarcinoma and its precursors as a model system. 38
16803510 2006
792
Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients. 38
16803480 2006
793
Evaluation of PTEN expression in cervical adenocarcinoma by tissue microarray. 38
16803514 2006
794
Fostering acceptance of human papillomavirus vaccines. 38
16729556 2006
795
High-risk human papillomavirus DNA testing: a marker for atypical glandular cells. 38
16470857 2006
796
Clinical significance of atypical glandular cells on cervical cytology. 38
16507944 2006
797
Minimal deviation endometrioid adenocarcinoma of the cervix: report of three cases with exfoliative cytology. 38
16511847 2006
798